<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer - Kokka, F - 2022 | Cochrane Library</title> <meta content="Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer - Kokka, F - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010260.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer - Kokka, F - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010260.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010260.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer" name="citation_title"/> <meta content="Fani Kokka" name="citation_author"/> <meta content="Queen Elizabeth The Queen Mother Hospital" name="citation_author_institution"/> <meta content="fani.kokka@nhs.net" name="citation_author_email"/> <meta content="Andrew Bryant" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Adeola Olaitan" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Elly Brockbank" name="citation_author"/> <meta content="St Bartholomew's Hospital" name="citation_author_institution"/> <meta content="Melanie Powell" name="citation_author"/> <meta content="St Bartholomew's Hospital" name="citation_author_institution"/> <meta content="David Oram" name="citation_author"/> <meta content="St. Bartholomew's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010260.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/08/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010260.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010260.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010260.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Chemoradiotherapy [adverse effects, methods]; Chemotherapy, Adjuvant [methods]; Hysterectomy; Neoadjuvant Therapy [methods]; *Uterine Cervical Neoplasms [drug therapy, radiotherapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010260.pub3&amp;doi=10.1002/14651858.CD010260.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZCrlluee";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010260\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010260\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010260.pub3",title:"Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer",firstPublishedDate:"Aug 22, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010260.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010260.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010260.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010260.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010260.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010260.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010260.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010260.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010260.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010260.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4046 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010260.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/appendices#CD010260-sec-0104"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/supinfo/CD010260StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/supinfo/CD010260StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#CD010260-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Fani Kokka</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#CD010260-cr-0005">Andrew Bryant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#CD010260-cr-0006">Adeola Olaitan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#CD010260-cr-0007">Elly Brockbank</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#CD010260-cr-0008">Melanie Powell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information#CD010260-cr-0009">David Oram</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information/en#CD010260-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 August 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010260.pub3">https://doi.org/10.1002/14651858.CD010260.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010260-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010260-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010260-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010260-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010260-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010260-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD010260-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010260-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010260-abs-0001" lang="en"> <section id="CD010260-sec-0001"> <h3 class="title" id="CD010260-sec-0001">Background</h3> <p>This is an update of the Cochrane Review published in Issue 4, 2015. Cervical cancer is one of the most frequent cause of death from gynaecological cancers worldwide. Many new cervical cancer cases in low‐income countries present at an advanced stage. Standard care in Europe and the US for locally advanced cervical cancer (LACC) is chemoradiotherapy. In low‐income countries, with limited access to radiotherapy, LACC may be treated with chemotherapy and hysterectomy. It is not certain if this improves survival. It is important to assess the value of hysterectomy with radiotherapy or chemotherapy, or both, as an alternative. </p> </section> <section id="CD010260-sec-0002"> <h3 class="title" id="CD010260-sec-0002">Objectives</h3> <p>To determine whether hysterectomy, in addition to standard treatment with radiotherapy or chemotherapy, or both, in women with LACC (Stage IB<sub>2</sub> to III) is safe and effective compared with standard treatment alone. </p> </section> <section id="CD010260-sec-0003"> <h3 class="title" id="CD010260-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE via Ovid, Embase via Ovid, LILACS, trial registries and the grey literature up to 3 February 2022. </p> </section> <section id="CD010260-sec-0004"> <h3 class="title" id="CD010260-sec-0004">Selection criteria</h3> <p>We searched for randomised controlled trials (RCTs) that compared treatments involving hysterectomy versus radiotherapy or chemotherapy, or both, in women with LACC International Federation of Gynecology and Obstetrics (FIGO) Stages IB<sub>2</sub> to III. </p> </section> <section id="CD010260-sec-0005"> <h3 class="title" id="CD010260-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We independently assessed study eligibility, extracted data and assessed the risk of bias. Where possible, we synthesised overall (OS) and progression‐free (PFS) or disease‐free (DFS) survival in a meta‐analysis using a random‐effects model. Adverse events (AEs) were incompletely reported and we described the results of single trials in narrative form. We used the GRADE approach to assess the certainty of the evidence. </p> </section> <section id="CD010260-sec-0006"> <h3 class="title" id="CD010260-sec-0006">Main results</h3> <p>From the searches we identified 968 studies. After deduplication, title and abstract screening, and full‐text assessment, we included 11 RCTs (2683 women) of varying methodological quality. This update identified four new RCTs and three ongoing RCTs. </p> <p>The included studies compared: hysterectomy (simple or radical) with radiotherapy or chemoradiotherapy or neoadjuvant chemotherapy (NACT) versus radiotherapy alone or chemoradiotherapy (CCRT) alone or CCRT and brachytherapy. There is also one ongoing study comparing three groups: hysterectomy with CCRT versus hysterectomy with NACT versus CCRT. </p> <p>There were two comparison groups for which we were able to do a meta‐analysis.</p> <p><b>Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone</b> </p> <p>Two RCTs with similar design characteristics (620 and 633 participants) found no difference in five‐year OS between NACT with hysterectomy versus CCRT. Meta‐analysis assessing 1253 participants found no evidence of a difference in risk of death (OS) between women who received NACT plus hysterectomy and those who received CCRT alone (HR 0.94, 95% CI 0.76 to 1.16; moderate‐certainty evidence). In both studies, the five‐year DFS in the NACT plus surgery group was worse (57%) compared with the CCRT group (65.6%), mostly for Stage IIB. </p> <p>Results of single trials reported no apparent difference in long‐term severe complications, grade 3 acute toxicity and severe late toxicity between groups (very low‐quality evidence). </p> <p><b>Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone</b> </p> <p>Meta‐analysis of three trials of NACT with hysterectomy versus radiotherapy alone, assessing 571 participants, found that women who received NACT plus hysterectomy had less risk of death (OS) than those who received radiotherapy alone (HR 0.71, 95% CI 0.55 to 0.93; I<sup>2</sup> = 0%; moderate‐quality evidence). However, a significant number of participants who received NACT plus hysterectomy also had radiotherapy. There was no difference in the proportion of women with disease progression or recurrence (DFS and PFS) between NACT plus hysterectomy and radiotherapy groups (RR 0.75, 95% CI 0.53 to 1.05; I<sup>2</sup> = 20%; moderate‐quality evidence). </p> <p>The certainty of the evidence was low or very‐low for all other comparisons for all outcomes. </p> <p>None of the trials reported quality of life outcomes.</p> </section> <section id="CD010260-sec-0007"> <h3 class="title" id="CD010260-sec-0007">Authors' conclusions</h3> <p>From the available RCTs, we found insufficient evidence that hysterectomy with radiotherapy, with or without chemotherapy, improves the survival of women with LACC who are treated with radiotherapy or CCRT alone. The overall certainty of the evidence was variable across the different outcomes and was universally downgraded due to concerns about risk of bias. The certainty of the evidence for NACT and radical hysterectomy versus radiotherapy alone for survival outcomes was moderate. The same occurred for the comparison involving NACT and hysterectomy compared with CCRT alone. Evidence from other comparisons was generally sparse and of low or very low‐certainty. This was mainly based on poor reporting and sparseness of data where results were based on single trials. More trials assessing medical management with and without hysterectomy may test the robustness of the findings of this review as further research is likely to have an important impact on our confidence in the estimate of effect. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010260-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010260-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010260-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010260-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010260-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010260-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010260-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010260-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010260-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010260-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD010260-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010260-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010260-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010260-abs-0002" lang="en"> <h3>Hysterectomy with medical management for cervical cancer that has spread to nearby tissues only </h3> <p><b>The issue</b> </p> <p>Cancer of the neck of the womb (cervical cancer) is the most common cancer among women up to 65 years of age. A high proportion of women in poor countries are diagnosed with locally advanced cervical cancer (spread to nearby tissues, but no obvious distant spread). They are usually treated with radiotherapy, with or without chemotherapy (medical treatment). Hysterectomy (surgery to remove the womb and the cervix) with medical treatment is also used, especially in poor countries where access to radiotherapy is limited. </p> <p><b>The aim of the review</b> </p> <p>Is hysterectomy with medical treatment more beneficial compared to medical treatment alone in women with locally advanced cervical cancer? </p> <p><b>How did we conduct the review?</b> </p> <p>A literature search from 1966 to February 2022 identified 11 clinical trials at moderate to high risk of bias. These included 2683 women and compared: hysterectomy with radiotherapy versus radiotherapy alone; hysterectomy with chemoradiotherapy (chemotherapy plus radiotherapy) versus chemoradiotherapy alone; hysterectomy with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy; and hysterectomy preceded by chemotherapy (neoadjuvant, to reduce the size of the cancer) versus radiotherapy alone. We also identified three ongoing trials. </p> <p><b>What are the main findings?</b> </p> <p><i>Hysterectomy (simple (womb and cervix) or radical (womb, cervix and surrounding tissues)) with neoadjuvant chemotherapy versus radiotherapy alone</i> </p> <p>By combining results from three studies that assessed 571 women, we found that fewer women who received neoadjuvant chemotherapy plus hysterectomy died than those who received radiotherapy alone. However, many women in the first group also had radiotherapy. There was no difference in the number of women who were disease‐free after treatment. </p> <p><i>Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone</i> </p> <p>We combined the results of two studies that assessed 1253 women. We found no difference in the risk of death between women who received hysterectomy with neoadjuvant chemotherapy and those who received chemoradiotherapy alone. </p> <p>Side effects were not well reported. Results of single trials showed no differences in severe side effects between groups in any comparison. Limited data suggested that the interventions appeared to be reasonably well tolerated, although more evidence is needed. </p> <p>Studies did not report how women's quality of life was affected.</p> <p><b>What are the conclusions?</b> </p> <p>We found insufficient evidence that hysterectomy added to radiotherapy and chemoradiation improved survival, quality of life or side effects in women with locally advanced cervical cancer compared with medical treatment alone. Overall, the quality of the evidence was variable and we had concerns about risk of bias. More trials assessing medical management with and without hysterectomy may test the robustness of the findings of this review. Further data from carefully planned trials assessing medical management with and without hysterectomy are likely to impact on how confident we are about these findings. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010260-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010260-sec-0099"></div> <h3 class="title" id="CD010260-sec-0100">Implications for practice</h3> <section id="CD010260-sec-0100"> <p>From the available randomised controlled trials (RCTs), we found insufficient evidence to suggest that hysterectomy improves the survival of women with locally advanced cervical cancer (LACC) who were treated with radiotherapy or chemoradiotherapy. We did find that women who received neoadjuvant chemotherapy plus hysterectomy had less risk of death than those who received radiotherapy alone, but it is unclear whether that survival benefit was attributable to the hysterectomy or chemotherapy, or because a significant number of these women also received adjuvant radiotherapy. The five‐year disease‐free survival in the neoadjuvant chemotherapy plus surgery group may have been slightly lower than in the concurrent chemoradiation group. </p> <p>The trials were at moderate or high risk of bias. The overall certainty of the evidence is variable across the different comparisons and outcomes and was often downgraded due to concerns over the risk of bias and incomplete reporting of outcomes. This downgrading was mainly based on poor reporting and sparseness of data for some of the comparisons, where results were based on a single trial. The imprecision in single trials may be due to the small sample sizes and few events. </p> <p>The decision to offer adjuvant hysterectomy (simple or radical, by open or laparoscopic procedure, with or without lymphadenectomy) needs to be individualised or performed in the context of a clinical trial. </p> </section> <h3 class="title" id="CD010260-sec-0101">Implications for research</h3> <section id="CD010260-sec-0101"> <p>None of the trials reported quality of life trials and adverse events were incompletely reported, so the quality of the evidence was low or very low for these outcomes across all comparisons. The trials in all of the comparisons were at high or moderate risk of bias. Further research is likely to have an important impact on our confidence in the estimates of effect and may change the estimates in the treatment comparisons based on single trial results and for outcomes that were incompletely reported. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010260-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010260-sec-0008"></div> <div class="table" id="CD010260-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone for women with locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (radical) with neoadjuvant chemotherapy versus with chemoradiotherapy alone for women with locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> NACT + hysterectomy </p> <p><b>Comparison:</b> CCRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 58.5–98.4 months in the 2 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.94</b> (0.76 to 1.16) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1253</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 0% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS</b> </p> <p>Median follow‐up 58.5–98.4 months in the 2 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.38</b> (1.02 to 1.87) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>633</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5‐year DFS in the NACT + surgery group was 57% vs 65.6% in the chemoradiotherapy group (P = 0.021) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>620</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>SAEs and toxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>SAEs</i> </p> <p>In first trial, there were no toxic deaths reported.</p> <p>198 SAEs occurred: 145 in the NACT + surgery arm vs 53 in the CCRT arm.</p> <p>In the second trial there were 114 grade 3 or 4 SAEs: 92 in the NACT + surgery arm vs 22 in the CCRT arm </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198</p> <p>(1 RCT)</p> <p>114</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><i>Toxicity</i> </p> <p>In 1 trial, NACT + surgery group, compared with the chemoradiotherapy group, there was a lower rate of rectal (5.7% with NACT + surgery vs 13.3% with chemoradiotherapy; P = 0.002), bladder (2.8% with NACT + surgery vs 7.3% with chemoradiotherapy; P = 0.017), and vaginal (19.9% with NACT + surgery vs 36.9% with chemoradiotherapy; P = 0.001) toxicity occurring or persisting 90 days after treatment completion. However, 24 months after treatment completion, there was no difference in rectal and bladder toxicities between groups, whereas vaginal toxicity continued to occur at a lower rate in the NACT + surgery group (12.0% with NACT + surgery vs 25.6% with chemoradiotherapy; P = 0.001). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><i>Treatment‐related morbidity</i> </p> <p>No treatment‐related deaths in either chemoradiotherapy or NACT + surgery arm. Overall, 89% of participants in the chemoradiotherapy arm and 73% in the NACT + surgery arm had complications, with 18% in NACT + surgery arm experiencing recurrence and requiring adjuvant radiotherapy. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CCRT:</b> concurrent chemoradiotherapy; <b>DFS:</b> disease‐free survival; <b>HR:</b> hazard ratio; <b>NACT:</b> neoadjuvant chemotherapy; <b>SAE:</b> serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to concerns regarding the uncertainty of risk of bias in individual trials and only two trials in meta‐analysis (although it is arguable whether the number of included participants represented relatively sparse data).<br/><sup>b</sup>Downgraded two levels due to risk of bias and sparse data.<br/><sup>c</sup>Downgraded three levels due to incomplete and poor reporting of important adverse events and toxicities, sparseness of data and risk of bias concerns. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010260-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone for women with locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone for women with locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> neoadjuvant chemotherapy + radical hysterectomy </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 39–60 months in the 3 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.71</b> (0.55 to 0.93) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐ or progression‐free survival</b> </p> <p>Median follow‐up 39–60 months in the 3 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.75</b> (0.53 to 1.05) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were varying definitions of disease‐ and progression‐free survival. However, we did not consider this merited further downgrading to low‐certainty evidence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Severe adverse events and toxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>Acute severe toxicity</i> </p> <p><b>RR 1.32</b> (0.47 to 3.71) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>Long‐term severe complications</i> </p> <p><b>RR 0.86</b> (0.49 to 1.50) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>409</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>Severe late toxicity</i> </p> <p><b>RR 0.60</b> (0.27 to 1.34) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to concerns regarding the uncertainty of risk of bias in individual trials.<br/><sup>b</sup>Downgraded two levels due to incomplete and poor reporting of important adverse events and toxicities and sparseness of data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010260-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> radiotherapy + hysterectomy (simple or radical) </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 9.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.89</b> (0.61 to 1.29) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 participants in each regimen (10% with radiotherapy + hysterectomy vs 9% with radiotherapy) were lost to follow‐up by 5 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> <p>Median follow‐up 9.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.77</b> </p> <p>(0.54 to 1.10)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 participants in each regimen (10% with radiotherapy + hysterectomy vs 9% with radiotherapy) were lost to follow‐up by 5 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tumour‐free actuarial survival at 5 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5‐year, tumour‐free actuarial survival for women with Stage IB was 80% in the preoperative radiotherapy + hysterectomy group and 89% in the radiotherapy group. In Stage IIA, these rates were 79% in the preoperative radiotherapy + hysterectomy group and 56% in the radiotherapy group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe/serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial stated that both treatment programmes were well tolerated and there were no differences between groups in adverse effects. There were 18/129 women with a grade 3 or 4 adverse effect in the radiotherapy + hysterectomy group and 19 cases in 18/121 women of severe adverse effects in the radiotherapy group. </p> <p>In another trial, only 1/48 (2%) women with Stage IB disease experienced a severe complication (grade 3) in the radiotherapy + hysterectomy group (ureteral stricture) whereas 5/40 experienced severe complications in the radiotherapy group (including rectovaginal fistula, vesicovaginal fistula, ureteral stricture and pelvic infection) (P &gt; 0.05). Similarly in women with Stage IIA disease, 5/14 (40%) women experienced a severe complication in the radiotherapy + hysterectomy group (including proctitis, rectal stricture, small bowel stricture and ureteral stricture) whereas only 1/16 women experienced a severe complication in the radiotherapy group (rectal stricture) (P &gt; 0.05). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>374</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative effect measures were not presented due to the crude combining of adverse events or sparse data, or both. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to sparse data leading to imprecision.<br/><sup>b</sup>Downgraded one level due to small number of trials and a lack of representation.<br/><sup>c</sup>Downgraded one level due to inadequate reporting of results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010260-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> chemoradiotherapy + hysterectomy (simple or radical) </p> <p><b>Comparison:</b> chemoradiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 3.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Overall survival was inadequately reported and it was not possible to calculate a hazard ratio. Overall survival time in the chemoradiotherapy + hysterectomy group was 6–40 months, median survival time was 23 months, and 3‐year survival rate was 82.7%. Total survival time in the chemoradiotherapy group was 5–41 months, median survival time was 22.5 months and 3‐year survival rate was 81.8%. Trial authors reported differences between arms were not statistically significant (P = 0.56). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression or event‐free survival</b> </p> <p>Median follow‐up 3.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival was inadequately reported in both trials and it was not possible to calculate a hazard ratio. In 1 trial, progression‐free survival time in the chemoradiotherapy + hysterectomy group was 3–40 months, median survival time was 23 months and 3‐year survival rate was 73.1%. The progression‐free survival time in the chemoradiotherapy alone group was 5–41 months, median survival time was 22 months and 3‐year survival rate was 64.8%. There was no significant difference between arms (P = 0.76). </p> <p>Another trial included 61 women and compared chemoradiotherapy + simple or radical hysterectomy vs chemoradiotherapy alone. There was no difference in 3‐year event‐free (death) survival rate (86% in the chemoradiotherapy + hysterectomy group vs 97% in the chemoradiotherapy alone group; log rank P = 0.15). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163<br/>(2 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not adequately reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe/serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not adequately reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to sparse data leading to imprecision.<br/><sup>b</sup>Downgraded one level due to small number of trials and a lack of representation. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010260-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Hysterectomy (simple or radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> chemoradiotherapy + hysterectomy (simple or radical) </p> <p><b>Comparison:</b> chemoradiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.65</b> (95% CI 0.35 to 1.21) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression or event‐free survival</b> </p> <p>Median follow‐up 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.70</b> (95% CI 0.31 to 1.34) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe late complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was no difference in the proportion of women with severe late complications in the brachytherapy and radical hysterectomy groups (P = 0.53). There were 4 cases of grade 3 or 4 proctitis in the brachytherapy group vs 2 cases in the radical hysterectomy group; 3 cases of severe cystitis in the brachytherapy group vs 0 in the radical hysterectomy group; 0 cases of grade 3 or 4 hydronephrosis in either group. </p> <p>Of the 211 participants, chemoradiotherapy with cisplatin and gemcitabine appeared to be reasonably well tolerated, although nearly a third of women experienced severe neutropenia (most grade 3). Of the 86 women who received a radical hysterectomy, the number of intraoperative and early surgical complications appeared to be reasonably low, with bleeding (9/86) being the most common. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to sparse data leading to imprecision.<br/><sup>b</sup>Downgraded one level due to small number of trials and a lack of representation. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010260-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010260-sec-0009"></div> <section id="CD010260-sec-0010"> <h3 class="title" id="CD010260-sec-0010">Description of the condition</h3> <p>Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women, with an estimated 604,000 new cases and 342,000 deaths worldwide in 2020 (<a href="./references#CD010260-bbs2-0038" title="HyunaS , JacquesF , RebeccaLS , MathieuL , IsabelleS , AhmedinJ , et al. Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2021;71(3):209-49. [PMID: 33538338]">Global Cancer Statistics 2020</a>). Rates remain disproportionately high in transitioning (countries with a low or medium Human Development Index (a measure that considers income, health and education to assess how well economies are doing)) versus transitioned (countries with a high or very high Human Development Index) countries (incidence: 18.8 per 100,000 in transitioning versus 11.3 per 100,000 in transitioned; mortality: 12.4 per 100,000 in transitioning versus 5.2 per 100,000 in transitioned). Mortality from cervical cancer has declined in many high‐income countries, particularly in countries with organised cervical cancer screening programmes; however, in low‐income countries, mortality has increased and it remains a major international problem (<a href="./references#CD010260-bbs2-0038" title="HyunaS , JacquesF , RebeccaLS , MathieuL , IsabelleS , AhmedinJ , et al. Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2021;71(3):209-49. [PMID: 33538338]">Global Cancer Statistics 2020</a>). Cervical cancer is considered nearly completely preventable with primary and secondary measures such as human papillomavirus vaccination and screening methods; however, these measures have not been equitably implemented across and within countries, resulting in the above inequality on incidence and mortality. The introduction in 1988 of a national cervical screening programme in the UK within a decade led to a halving in the incidence of cervical cancer, from an age‐standardised incidence rate of 16.2 per 100,000 to an age‐standardised incidence rate of 8.3 per 100,000 in 2008 (<a href="./references#CD010260-bbs2-0065" title="National Cancer Intelligence Network. Cervical cancer incidence and screening coverage. www.ncin.org.uk/publications/data_briefings/cervical_incidence_and_screening (accessed prior to 29 April 2022).">NCIN 2010</a>). In many transitioning countries, access to health services is limited and screening for cervical cancer is either absent or reaches few of the women who need it. In these areas, cervical cancer is the most common cancer in women and the leading cause of cancer death (<a href="./references#CD010260-bbs2-0038" title="HyunaS , JacquesF , RebeccaLS , MathieuL , IsabelleS , AhmedinJ , et al. Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2021;71(3):209-49. [PMID: 33538338]">Global Cancer Statistics 2020</a>; <a href="./references#CD010260-bbs2-0059" title="MathersC , BoermaT , FatDM . The global burden of disease: 2004 update. www.who.int/publications/i/item/9789241563710 (accessed 29 April 2020).">Mathers 2008</a>). </p> <p>In 2018, the World Health Organization called for global action to reduce incidence of cervical cancer (to 4 per 100,000 or less worldwide) by adopting a triple intervention strategy of vaccinating young girls by the age of 15 years, screening of women twice in the age range of 35 to 45 years and treating at least 90% of the precancer lesions detected through screening (<a href="./references#CD010260-bbs2-0038" title="HyunaS , JacquesF , RebeccaLS , MathieuL , IsabelleS , AhmedinJ , et al. Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2021;71(3):209-49. [PMID: 33538338]">Global Cancer Statistics 2020</a>). In the meantime, many women are diagnosed at an advanced stage that is more difficult to treat. Naga and colleagues reported that more than two‐thirds of women have advanced disease at diagnosis and approximately 85% occur in transitioning countries (<a href="./references#CD010260-bbs2-0062" title="Naga ChP , GurramL , ChopraS , MahantshettyU . The management of locally advanced cervical cancer. Current Opinions in Oncology2018;30(5):323-9. [PMID: 29994902.]">Naga 2018</a>). Another report from a transitioning country has shown that over 80% of new cervical cancer cases are found at advanced stages (Stage IB<sub>2</sub> or more), and over half of these are Stage III to IV (<a href="./references#CD010260-bbs2-0049" title="KhuhapremaT , SrivatanakulP , SriplungH , WiangnonS , SumitsawanY , AttasaraP . Cancer in Thailand 2001–2003. Bangkok: National Cancer Institute2010;V:3-76.">Khuhaprema 2010</a>). </p> <p>Cervical cancer is staged according to the International Federation of Gynecology and Obstetrics (FIGO) system (<a href="./appendices#CD010260-sec-0105">Appendix 1</a>). Since the publication of the first review, the FIGO staging of cervical cancer has changed (<a href="./references#CD010260-bbs2-0080" title="SinghN , RousB , GanesanR . 2018 FIGO staging system for cervical cancer: summary and comparison with 2009 FIGO staging system. www.bgcs.org.uk/wp-content/uploads/2019/05/BAGP-2018-FIGO-Cervix-Ca-staging-doc-v1.2.pdf (accessed prior to 4 January 2021).">Singh 2019</a>; <a href="#CD010260-tbl-0006">Table 1</a>). Prior to this, FIGO staging for cervical cancer was based mainly on clinical examination (<a href="./references#CD010260-bbs2-0070" title="PecorelliS , ZiglianiL , OdicinoF . Revised FIGO staging for carcinoma of the cervix. International Journal Gynecology and Obstetrics2009;205(2):107-8.">Percorelli 2009</a>). In 2018, this approach was revised to allow imaging (r) and pathology (p) findings, where available, to assign stage (<a href="./references#CD010260-bbs2-0025" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>). The most important changes were as follows. </p> <div class="table" id="CD010260-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of 2009 and 2018 FIGO staging of cervical cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Stage I (2018): carcinoma strictly confined to the cervix (extension to the uterine corpus should be disregarded) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2009 FIGO stage: description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2018 FIGO stage: description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IA: invasive carcinoma diagnosed only by microscopy, with maximum depth of invasion &lt;/= 5 mm and largest extension &lt;/= 7 mm</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IA: invasive carcinoma diagnosed only by microscopy, with maximum depth of invasion &lt; 5 mm</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>– Lateral extent of the carcinoma is no longer considered in distinguishing between FIGO Stage IA and IB carcinomas</b> </p> <p><b>– If margins of loop are involved patient is allocated to Stage IB1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0001"> <li> <p>IA1: measured stromal invasion &lt; 3 mm in depth and extension &lt;/= 7 mm</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0002"> <li> <p>IA1: measured stromal invasion &lt; 3 mm in depth</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0003"> <li> <p>IA2: measured stromal invasion &gt;/= 3 mm and &lt; 5 mm in depth and extension &lt;/= 7 mm</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0004"> <li> <p>IA2: measured stromal invasion &gt;/= 3 mm and &lt; 5 mm in depth</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IB: clinically visible lesions limited to the cervix or preclinical cancers greater than Stage IA </i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IB: invasive carcinoma with measured deepest invasion &gt;/= 5 mm (greater than Stage IA), lesion limited to the cervix uteri</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– See above</b> </p> <p><b>– LVSI must be commented upon, although does not affect FIGO stage</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD010260-list-0005"> <li> <p>IB1: clinically visible lesion &lt;/= 4 cm in greatest dimension</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB1: invasive carcinoma &gt;/= 5 mm depth of stromal invasion, and &lt; 2 cm in greatest dimension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– New stage category</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB2: invasive carcinoma &gt;/= 2 cm and &lt; 4 cm in greatest dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– New stage category</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB2: invasive carcinoma &gt; 4 cm in greatest dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB3: invasive carcinoma &gt;/= 4 cm in greatest dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– New stage category</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Adapted from <a href="./references#CD010260-bbs2-0080" title="SinghN , RousB , GanesanR . 2018 FIGO staging system for cervical cancer: summary and comparison with 2009 FIGO staging system. www.bgcs.org.uk/wp-content/uploads/2019/05/BAGP-2018-FIGO-Cervix-Ca-staging-doc-v1.2.pdf (accessed prior to 4 January 2021).">Singh 2019</a>.<br/>LVSI: lymphovascular space invasion. </p> </div> </div> <p> <ul id="CD010260-list-0006"> <li> <p>The horizontal dimension is no longer considered in defining the upper boundary of a Stage IA carcinoma. </p> </li> <li> <p>The diagnosis of Stage IA<sub>1</sub> and IA<sub>2</sub> carcinomas is made on microscopic examination of a surgical specimen, which includes the entire lesion. The margins of an excision specimen should be reported to be negative for disease. </p> </li> <li> <p>If the margins of the cone biopsy are positive for invasive cancer, the patient is assigned to Stage IB<sub>1</sub>. </p> </li> <li> <p>Stage IB has been subdivided into IB<sub>1</sub>, IB<sub>2</sub> and IB<sub>3</sub> based on maximum tumour size. </p> </li> <li> <p>The revised 2018 system includes nodal status; the presence of nodal involvement in a tumour of any size upstages the case to Stage IIIC, with IIIC<sub>1</sub> indicating pelvic and IIIC<sub>2</sub> indicating para‐aortic nodal involvement. The revised FIGO classification is thereby now more closely aligned with the structure of the TNM classification, which is a classification system of cancer that describes the size of the tumour and any spread of cancer into nearby tissue (T); it describes spread of cancer to nearby lymph nodes (N); and it also describes metastasis (spread of cancer to other parts of the body) (M) (<a href="./references#CD010260-bbs2-0025" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>). </p> </li> </ul> </p> <p>Remaining or recurrent disease frequently occurs after initial treatment in more than 50% of Stage III to IVA cervical cancer, leading to mortality (<a href="./appendices#CD010260-sec-0105">Appendix 1</a>). </p> <p>In this review, women with locally advanced cervical cancer (LACC) were the population of interest. It is likely that the included studies used the 2009 FIGO classification system (<a href="./references#CD010260-bbs2-0070" title="PecorelliS , ZiglianiL , OdicinoF . Revised FIGO staging for carcinoma of the cervix. International Journal Gynecology and Obstetrics2009;205(2):107-8.">Percorelli 2009</a>), as the new system was introduced in 2018 (<a href="./references#CD010260-bbs2-0025" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>). </p> </section> <section id="CD010260-sec-0011"> <h3 class="title" id="CD010260-sec-0011">Description of the intervention</h3> <p>Treatment decisions for invasive cervical cancer should be individualised and based on factors such as age, medical condition of the women, stage of disease and other tumour‐related factors in order to yield the best cure with minimum complications (<a href="./references#CD010260-bbs2-0048" title="KesicV . Management of cervical cancer. European Journal of Surgical Oncology2006;32:832-7.">Kesic 2006</a>). As a general rule, multiple treatment modalities have more potential complications and adverse effects than one treatment modality. </p> <p>For Stage IA<sub>1</sub>, local cervical treatments (large loop or needle excision of the transformation zone (LLETZ/NETZ), knife cone biopsy) or total hysterectomy (surgery to remove the womb and the neck of the womb) can be used, depending on women's preferences and fertility aspirations. </p> <p>For Stage IA<sub>2</sub> to IB<sub>1</sub>, radical hysterectomy with pelvic lymphadenectomy or chemoradiotherapy have been the accepted treatment modalities with reported similar efficacies (<a href="./references#CD010260-bbs2-0035" title="EifelPJ . Radiotherapy versus radical surgery for gynecologic neoplasms: carcinomas of the cervix and vulva. Frontiers of Radiation Therapy and Oncology1993;27:130-42.">Eifel 1993</a>). This finding was supported mainly by a randomised controlled trial (RCT) before the concurrent chemoradiotherapy (CCRT) era (<a href="./references#CD010260-bbs2-0052" title="LandoniF , ManeoA , ColomboA , PlacaF , MilaniR , PeregoP , et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet1997;350(9077):535-40.">Landoni 1997</a>). In younger women, surgery is preferred, partly because of the advantage of preservation of ovarian function. </p> <p>Radical hysterectomy, and bilateral pelvic lymphadenectomy, involves the removal of the uterus, the cervix, the upper part of the vagina and the tissues around the cervix (parametrial tissue), as well as the lymph nodes (glands) in the pelvis to determine if they contain cancer cells (pelvic lymphadenectomy). Although this type of surgery has excellent results, it can result in adverse effects such as organ injury (bladder, bowel, blood vessel, nerve) and long‐term adverse effects such as sexual or bladder dysfunction, pelvic cyst formation and lymphoedema (swelling) of the legs. </p> <p>Radical trachelectomy may be an alternative to radical hysterectomy in women who want to preserve their fertility, provided they meet certain criteria. These are tumour size 2 cm or less and no metastasis to regional lymph nodes (<a href="./references#CD010260-bbs2-0079" title="ShepherdJH . Cervical cancer. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2012;26(3):293-309.">Shepherd 2012</a>). Radical trachelectomy involves removing the cervix, the upper part of the vagina and the parametrial tissue and the pelvic lymph glands. This treatment is well‐established, appears to be safe and effective in preserving fertility, and has a high chance of conception. Late miscarriage and premature labour are the most serious adverse effects in pregnancies where the women have had a trachelectomy. </p> <p>For Stage IB<sub>2</sub> tumours and above, the incidence of lymph node metastasis increases significantly, as well as the incidence of central, regional and distant recurrences (<a href="./references#CD010260-bbs2-0021" title="AlvarezRD , SoongSJ , KinneyWK , ReidGC , SchrayMF , PodratzKC , et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecologic Oncology1989;36:130-5.">Alvarez 1989</a>; <a href="./references#CD010260-bbs2-0027" title="BurghardtE , PickelH . Local spread and lymph node involvement in cervical cancer. Obstetrics and Gynecology1978;52:138-45.">Burghardt 1978</a>; <a href="./references#CD010260-bbs2-0029" title="ChungCK , NahhasWA , StrykerJA , CurrySL , AbtAB , MortelR . Analysis of factors contributing to treatment failures in stage IB and IIA carcinoma of the cervix. American Journal of Obstetrics and Gynecology1980;138:550-6.">Chung 1980</a>; <a href="./references#CD010260-bbs2-0033" title="DelgadoE , BundyB , ZainoR , SevinBU , CreasmanWT , MajorF . Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic Oncology1990;38:352-7.">Delgado 1990</a>; <a href="./references#CD010260-bbs2-0072" title="PiverMS , ChungWS . Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstetrics and Gynecology1975;46(5):507-10.">Piver 1975</a>). If a surgical approach is chosen, there may be difficulties in removing all of the tumour with a margin of normal tissue (that is adequate surgery), therefore there is a high probability of requiring additional treatment (radiotherapy with or without chemotherapy) with the increased morbidity of combined treatment. For women with FIGO Stage IB<sub>2</sub> disease and higher, chemoradiotherapy is now standard care; it has been shown to improve disease‐free survival (DFS), progression‐free survival (PFS) and overall survival (OS) (<a href="./references#CD010260-bbs2-0028" title="Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD008285. [DOI: 10.1002/14651858.CD008285]">CCCMAC 2010</a>; <a href="./references#CD010260-bbs2-0063" title="National Cancer Institute. NCI clinical announcement. United States Department of Health and Human Services, Public Health Service, National Institutes of Health February 1999; Bethesda (MD).">NCI 1999</a>). It involves administration of cisplatin‐based chemotherapy during the course of radiotherapy, all delivered within seven weeks. The chemotherapy makes the cancer cells more sensitive to the radiotherapy and therefore improves the treatment results. </p> <p>However, surgery in LACC (Stage IB<sub>2</sub> to III) has been considered in the following cases: </p> <p> <ul id="CD010260-list-0007"> <li> <p>after chemoradiotherapy, for those in whom no complete remission is achieved within two to three months following treatment, the tumour is oncologically operable and the woman is clinically fit to undergo additional surgery; </p> </li> <li> <p>after either radiotherapy or chemotherapy are used to shrink the cervical tumour to a size where it can be removed with normal margins; </p> </li> <li> <p>following neoadjuvant chemotherapy (NACT; chemotherapy given before other treatments to reduce the size of the tumour), especially in transitioning countries with limited access to radiotherapy, but it remains unclear whether it offers a benefit over surgery alone or chemoradiotherapy (<a href="./references#CD010260-bbs2-0076" title="RydzewskaL , TierneyJ , ValeCL , SymondsPR . Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD007406. [DOI: 10.1002/14651858.CD007406.pub3]">Rydzewska 2012</a>). </p> </li> </ul> </p> <p>Stage IVA cervical cancer, where the cancer has spread to the adjacent bladder or rectum, is usually treated with chemoradiotherapy (<a href="./references#CD010260-bbs2-0028" title="Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD008285. [DOI: 10.1002/14651858.CD008285]">CCCMAC 2010</a>). Some authors have suggested that NACT plus radical surgery (including removal of the affected bladder or rectum) might be a valid alternative to standard treatment (<a href="./references#CD010260-bbs2-0024" title="Benedetti PaniciP , BellatiF , ManciN , PerniceM , PlottiF , Di DonatoV , et al. Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer. Annals of Surgical Oncology2007;14(9):2643-8.">Benedetti Panici 2007</a>). </p> <p>For Stage IVB, the aim of treatment is generally palliative radiotherapy and chemotherapy (<a href="./references#CD010260-bbs2-0048" title="KesicV . Management of cervical cancer. European Journal of Surgical Oncology2006;32:832-7.">Kesic 2006</a>; <a href="./references#CD010260-bbs2-0064" title="National Cancer Institute. Stage IVB cervical cancer treatment. www.cancer.gov/cancertopics/pdq/treatment/cervical/HealthProfessional/page9 (accessed prior to 29 April 2022).">NCI 2014</a>). </p> </section> <section id="CD010260-sec-0012"> <h3 class="title" id="CD010260-sec-0012">How the intervention might work</h3> <p>Although surgical resection of advanced non‐metastatic forms of cervical cancer is controversial, it may help improve local control (<a href="./references#CD010260-bbs2-0046" title="HouvenaeghelG , MartinoM , BladouF , MoutardierV , TernierF , DelperoJR , et al. Value of surgery in the treatment of advanced cervical cancers. Annales de Chirurgie1998;52:425-33.">Houvenaeghel 1998</a>). Many studies report favourable outcomes of hysterectomy for women with advanced cervical cancer after radiotherapy (<a href="./references#CD010260-bbs2-0030" title="ClasseJM , RauchP , RodierJF , MoriceP , StoeckleE , LasryS , et al. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecologic Oncology2006;102:523-9.">Classe 2006</a>; <a href="./references#CD010260-bbs2-0050" title="KornovskiY , GorchevG . Histopathological findings in postoperative specimens in cervical cancer patients with stages IB2–IVA after neoadjuvant chemotherapy and preoperative plus postoperative radiotherapy. Journal of the Balkan Union of Oncology2007;12:57-63.">Kornovski 2007</a>; <a href="./references#CD010260-bbs2-0055" title="LeinoR , GrenmanS , RantanenV , KiilholmaP , SalmiT . Operative treatment of advanced cervical cancer after full pelvic irradiation. Annales Chirurgiae et Gynaecologiae1994;208(Suppl):50-3.">Leino 1994</a>; <a href="./references#CD010260-bbs2-0066" title="NotermanD , PhilippsonC , HertensD , VeysI , SchobbensJC , NogaretJM . Neoadjuvant radiochemotherapy and surgery of locally advanced cervical carcinoma: review of 22 patients treated at the Bordet Institute. Journal de Gynecologie Obstetrique et Biologie de la Reproduction2006;35:23-7.">Noterman 2006</a>; <a href="./references#CD010260-bbs2-0073" title="PotishRA , TwiggsLB , PremKA , CarsonLF , AdcockLL . Surgical intervention following multimodality therapy for advanced cervical cancer. Gynecologic Oncology1990;38:175-80.">Potish 1990</a>; <a href="./references#CD010260-bbs2-0082" title="TsudaH , TanakaM , ManabeT , NakataS , IshikoO , YamamotoK . Phase I–II study of neoadjuvant chemoradiotherapy followed by radical surgery in locally advanced cervical cancer. Anticancer Drugs2001;12:853-8.">Tsuda 2001</a>; <a href="./references#CD010260-bbs2-0083" title="WangY , CaoP , ZhangX , ZengQ . Combined treatment for locally advanced carcinoma of uterine cervix. Zhonghua Zhong Liu Za Zhi2002;24:508-10.">Wang 2002</a>). Whether simple total hysterectomy (<a href="./references#CD010260-bbs2-0055" title="LeinoR , GrenmanS , RantanenV , KiilholmaP , SalmiT . Operative treatment of advanced cervical cancer after full pelvic irradiation. Annales Chirurgiae et Gynaecologiae1994;208(Suppl):50-3.">Leino 1994</a>; <a href="./references#CD010260-bbs2-0073" title="PotishRA , TwiggsLB , PremKA , CarsonLF , AdcockLL . Surgical intervention following multimodality therapy for advanced cervical cancer. Gynecologic Oncology1990;38:175-80.">Potish 1990</a>; <a href="./references#CD010260-bbs2-0083" title="WangY , CaoP , ZhangX , ZengQ . Combined treatment for locally advanced carcinoma of uterine cervix. Zhonghua Zhong Liu Za Zhi2002;24:508-10.">Wang 2002</a>) or radical hysterectomy (<a href="./references#CD010260-bbs2-0030" title="ClasseJM , RauchP , RodierJF , MoriceP , StoeckleE , LasryS , et al. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecologic Oncology2006;102:523-9.">Classe 2006</a>; <a href="./references#CD010260-bbs2-0050" title="KornovskiY , GorchevG . Histopathological findings in postoperative specimens in cervical cancer patients with stages IB2–IVA after neoadjuvant chemotherapy and preoperative plus postoperative radiotherapy. Journal of the Balkan Union of Oncology2007;12:57-63.">Kornovski 2007</a>; <a href="./references#CD010260-bbs2-0066" title="NotermanD , PhilippsonC , HertensD , VeysI , SchobbensJC , NogaretJM . Neoadjuvant radiochemotherapy and surgery of locally advanced cervical carcinoma: review of 22 patients treated at the Bordet Institute. Journal de Gynecologie Obstetrique et Biologie de la Reproduction2006;35:23-7.">Noterman 2006</a>; <a href="./references#CD010260-bbs2-0082" title="TsudaH , TanakaM , ManabeT , NakataS , IshikoO , YamamotoK . Phase I–II study of neoadjuvant chemoradiotherapy followed by radical surgery in locally advanced cervical cancer. Anticancer Drugs2001;12:853-8.">Tsuda 2001</a>; <a href="./references#CD010260-bbs2-0083" title="WangY , CaoP , ZhangX , ZengQ . Combined treatment for locally advanced carcinoma of uterine cervix. Zhonghua Zhong Liu Za Zhi2002;24:508-10.">Wang 2002</a>) is needed is unclear (<a href="./references#CD010260-bbs2-0066" title="NotermanD , PhilippsonC , HertensD , VeysI , SchobbensJC , NogaretJM . Neoadjuvant radiochemotherapy and surgery of locally advanced cervical carcinoma: review of 22 patients treated at the Bordet Institute. Journal de Gynecologie Obstetrique et Biologie de la Reproduction2006;35:23-7.">Noterman 2006</a>). </p> <p>Multimodal treatment of hysterectomy combined with chemotherapy or radiotherapy, or both, may improve survival; but it may (<a href="./references#CD010260-bbs2-0042" title="HequetD , MarchandE , PlaceV , FourchotteV , De La RochefordièreA , DridiS , et al. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study. European Journal of Surgical Oncology2013;39(12):1428-34. [DOI: 10.1016/j.ejso.2013.10.006]">Hequet 2013</a>) or may not (<a href="./references#CD010260-bbs2-0030" title="ClasseJM , RauchP , RodierJF , MoriceP , StoeckleE , LasryS , et al. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecologic Oncology2006;102:523-9.">Classe 2006</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>) cause significantly worse adverse events compared with radiotherapy or chemoradiotherapy alone. </p> </section> <section id="CD010260-sec-0013"> <h3 class="title" id="CD010260-sec-0013">Why it is important to do this review</h3> <p>It is important to assess the value of hysterectomy in addition to chemotherapy, radiotherapy or chemoradiotherapy in the treatment of LACC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010260-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010260-sec-0014"></div> <p>To determine whether hysterectomy, in addition to standard treatment with radiotherapy or chemotherapy, or both, in women with LACC (Stage IB<sub>2</sub> to III) is safe and effective compared with standard treatment alone. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010260-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010260-sec-0015"></div> <section id="CD010260-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010260-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD010260-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women (aged 18 years or older) with LACC (Stage IB<sub>2</sub> to III). </p> </section> <section id="CD010260-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We compared hysterectomy in combination with neoadjuvant, concurrent or adjuvant therapy versus non‐surgical interventions. </p> <p> <ul id="CD010260-list-0008"> <li> <p>Hysterectomy (radical) with NACT versus chemoradiotherapy alone.</p> </li> <li> <p>Hysterectomy (simple or radical) with NACT versus radiotherapy alone.</p> </li> <li> <p>Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone.</p> </li> <li> <p>Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone.</p> </li> <li> <p>Hysterectomy (radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy. </p> </li> <li> <p>Hysterectomy (radical) with chemoradiotherapy versus hysterectomy (radical) with NACT versus chemoradiotherapy alone. </p> </li> </ul> </p> </section> <section id="CD010260-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010260-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010260-list-0009"> <li> <p>Overall survival (OS): survival until death from all causes assessed from the time when women were enrolled in the study, or as defined by the trial authors. </p> </li> </ul> </p> </section> <section id="CD010260-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010260-list-0010"> <li> <p>Progression‐free survival (PFS).</p> </li> <li> <p>If authors reported disease‐free survival (DFS) rather than PFS then this was assessed.</p> </li> <li> <p>Quality of life measures using a scale that had been validated through reporting of norms against a validated scale in a peer‐reviewed publication. </p> </li> <li> <p>Severe adverse events</p> <ul id="CD010260-list-0011"> <li> <p>Surgery‐related complications: measured as the proportion of women who developed one of the items below (according to the study definition) within 12 weeks. These were classified as either early (before discharge from hospital or within seven days of surgery), late (from seven days to within 12 weeks of surgery), or total complications (early and late): </p> <ul id="CD010260-list-0012"> <li> <p>any postoperative infection;</p> </li> <li> <p>surgery‐related injuries (blood vessel, nerve, bladder, bowel);</p> </li> <li> <p>excessive blood loss (according to the study definition);</p> </li> <li> <p>thromboembolic events;</p> </li> <li> <p>any anaesthesiological complications;</p> </li> <li> <p>other severe adverse event;</p> </li> <li> <p>fistula formation;</p> </li> <li> <p>voiding or bladder dysfunction;</p> </li> <li> <p>lymphocysts or lymphoedema;</p> </li> <li> <p>psychosexual dysfunction.</p> </li> </ul> </li> <li> <p>Chemotherapy‐ and radiotherapy‐related complications: grades of chemotherapeutic and radiotherapeutic toxicity were extracted and grouped as: </p> <ul id="CD010260-list-0013"> <li> <p>haematological (leukopenia, anaemia, thrombocytopenia, neutropenia, haemorrhage);</p> </li> <li> <p>gastrointestinal (nausea, vomiting, anorexia, diarrhoea, liver toxicity, proctitis);</p> </li> <li> <p>genitourinary;</p> </li> <li> <p>skin (stomatitis, mucositis, alopecia, allergy);</p> </li> <li> <p>neurological (peripheral and central); and</p> </li> <li> <p>pulmonary.</p> </li> </ul> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD010260-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We sought papers in all languages and conducted translations where necessary.</p> <section id="CD010260-sec-0024"> <h4 class="title">Electronic searches</h4> <p>See: Cochrane Gynaecological Cancer Group methods used in reviews (<a href="http://gnoc.cochrane.org" target="_blank">gnoc.cochrane.org</a>). </p> <p>For this update, we searched the following electronic databases on 3 February 2022:</p> <p> <ul id="CD010260-list-0014"> <li> <p>the Cochrane Register of Controlled Trials (CENTRAL; 2022, Issue 2), in the Cochrane Library <a href="./appendices#CD010260-sec-0106">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (1946 to 4 February 2022) <a href="./appendices#CD010260-sec-0107">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (1980 to 2022 week 4) <a href="./appendices#CD010260-sec-0108">Appendix 4</a>; </p> </li> <li> <p>LILACS (February 2022) <a href="./appendices#CD010260-sec-0109">Appendix 5</a>. </p> </li> </ul> </p> <p>All relevant articles that were found were identified on PubMed and, using the 'related articles' feature, we carried out further searches for newly published articles. </p> </section> <section id="CD010260-sec-0025"> <h4 class="title">Searching other resources</h4> <section id="CD010260-sec-0026"> <h5 class="title">Unpublished and grey literature</h5> <p>We conducted a Google search for Internet‐based resources and open‐access publications. We searched Metaregister (<a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled-trials.com/rct</a>), Physicians Data Query (<a href="http://www.nci.nih.gov" target="_blank">www.nci.nih.gov</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), and the National Cancer Institute (<a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a>) for ongoing trials. One trial was identified through these searches; this trial closed to recruitment in September 2014. We contacted the principal investigator for more details and preliminary results, but have not yet received a reply. Therefore, we have added this trial to the <a href="./references#CD010260-bbs1-0003" title="">Ongoing studies</a> section. </p> <p>We searched conference proceedings and abstracts through ZETOC (<a href="http://zetoc.mimas.ac.uk" target="_blank">zetoc.mimas.ac.uk</a>) and WorldCat Dissertations. </p> </section> <section id="CD010260-sec-0027"> <h5 class="title">Handsearching</h5> <p>We handsearched the citation lists of included studies, key textbooks and previous systematic reviews. </p> <p>We handsearched reports/websites/conferences of the following:</p> <p> <ul id="CD010260-list-0015"> <li> <p>International Gynecological Cancer Society (IGCS);</p> </li> <li> <p>European Society of Gynaecological Oncology (ESGO);</p> </li> <li> <p>Society of Gynecologic Oncologists (SGO);</p> </li> <li> <p>British Gynaecological Cancer Society (BGCS);</p> </li> <li> <p>Australian Society of Gynaecologic Oncologists (ASGO);</p> </li> <li> <p>American Society of Clinical Oncology (ASCO);</p> </li> <li> <p>European Society of Medical Oncology (ESMO);</p> </li> <li> <p>Clinical Oncological Society of Australia (COSA).</p> </li> </ul> </p> </section> </section> </section> <section id="CD010260-sec-0028"> <h3 class="title" id="CD010260-sec-0028">Data collection and analysis</h3> <section id="CD010260-sec-0029"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to the reference management database, Endnote. We removed duplicates and two review authors (AB, FK) independently examined the remaining references. We excluded those studies that clearly did not meet the inclusion criteria and obtained the full texts of potentially relevant references. Two review authors (AB, FK) independently assessed the eligibility of the retrieved papers. We resolved disagreements by discussion between the two review authors with a final review by the other authors (EB, MP, DO). Reasons for exclusion are documented. </p> </section> <section id="CD010260-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>For included studies, we abstracted data as recommended in Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010260-bbs2-0044" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). The data included the following: </p> <p> <ul id="CD010260-list-0016"> <li> <p>author, year of publication and journal citation (including language);</p> </li> <li> <p>country;</p> </li> <li> <p>setting;</p> </li> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>study design, methodology;</p> </li> <li> <p>study population:</p> <ul id="CD010260-list-0017"> <li> <p>total number enrolled;</p> </li> <li> <p>patient characteristics;</p> </li> <li> <p>age;</p> </li> <li> <p>comorbidities;</p> </li> <li> <p>type of initial or primary treatment (chemotherapy, chemoradiation, or radiotherapy), including details on dose, duration and combination; </p> </li> <li> <p>performance status;</p> </li> </ul> </li> <li> <p>advanced cervical cancer details at diagnosis:</p> <ul id="CD010260-list-0018"> <li> <p>stage;</p> </li> <li> <p>grade;</p> </li> <li> <p>histology;</p> </li> </ul> </li> <li> <p>intervention (hysterectomy) details:</p> <ul id="CD010260-list-0019"> <li> <p>type of hysterectomy (total or subtotal, simple or radical with/without pelvic lymphadenectomy);</p> </li> <li> <p>timing of hysterectomy;</p> </li> <li> <p>prevention of complications (prophylactic antibiotics or any other measures);</p> </li> <li> <p>grade or prior training of surgeon;</p> </li> </ul> </li> <li> <p>comparison details:</p> <ul id="CD010260-list-0020"> <li> <p>details of dose and duration of chemotherapeutic, radiotherapeutic or a combination treatment used; </p> </li> <li> <p>method of primary treatment administration;</p> </li> <li> <p>drug regimen;</p> </li> </ul> </li> <li> <p>local control, for example, bleeding, pressure symptoms, pain;</p> </li> <li> <p>risk of bias in study (assessment of risk of bias in included studies);</p> </li> <li> <p>duration of follow‐up;</p> </li> <li> <p>outcomes, OS and PFS, quality of life and severe adverse events:</p> <ul id="CD010260-list-0021"> <li> <p>for each outcome, outcome definition (with diagnostic criteria if relevant);</p> </li> <li> <p>unit of measurement (if relevant);</p> </li> <li> <p>for scales, upper and lower limits, and whether high or low score is good;</p> </li> <li> <p>results, number of participants allocated to each intervention group and</p> </li> <li> <p>for each outcome of interest, sample size, missing participants.</p> </li> </ul> </li> </ul> </p> <p>We extracted data on outcomes as follows.</p> <p> <ul id="CD010260-list-0022"> <li> <p>For time to event (OS and PFS) data, we extracted the log of the hazard ratio (HR) (log(HR)) and its standard error from trial reports. If these were not reported, we attempted to estimate them from other reported statistics using the methods of <a href="./references#CD010260-bbs2-0069" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>. </p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events), we extracted the number of participants in each treatment arm who experience the outcome of interest and the number of participants. </p> </li> </ul> </p> <p>These were assessed at the endpoint in order to estimate a risk ratio (RR) and 95% confidence interval (CI). </p> <p>Where possible, all the data extracted were those relevant to an intention‐to‐treat analysis in which the participants were analysed in the groups to which they were assigned. We noted the time points at which outcomes were collected and reported. </p> <p>Two review authors (AB, FK) abstracted data independently onto a data abstraction form specially designed for the review. We resolved differences between review authors by discussion. </p> <p>For continuous outcomes (e.g. quality of life), we had planned to extract the final value and standard deviation of the outcome of interest and the number of women assessed at the endpoint in each treatment arm at the end of follow‐up, in order to estimate the mean difference (if trials measured outcomes on the same scale) or standardised mean difference (if trials measured outcomes on different scales) between treatment arms and its standard error. However, none of the trials reported continuous outcome data for the quality of life. </p> </section> <section id="CD010260-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in the included RCTs in accordance with the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> using the Cochrane’s RoB 1 tool and the criteria specified in Chapter 8 (<a href="./references#CD010260-bbs2-0044" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). This included assessment of: </p> <p> <ul id="CD010260-list-0023"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (restricted to blinding of outcome assessors as it was not possible to blind participants or investigators to these treatment modalities); </p> </li> <li> <p>incomplete outcome data, we recorded the proportion of participants whose outcomes were not reported at the end of the study. We coded the satisfactory level of losses to follow‐up for each outcome as: </p> <ul id="CD010260-list-0024"> <li> <p>yes, if less than 20% of participants were lost to follow‐up and reasons for loss to follow‐up were similar in both treatment arms; </p> </li> <li> <p>no, if 20% or greater of participants were lost to follow‐up or reasons for loss to follow‐up were different between treatment arms; </p> </li> <li> <p>unclear, if loss to follow‐up was not reported;</p> </li> </ul> </li> <li> <p>selective reporting of outcomes;</p> </li> <li> <p>other possible sources of bias.</p> </li> </ul> </p> <p>Two review authors (FK, AB) applied the risk of bias tool independently and resolved differences by discussion. Results were summarised in a risk of bias summary and graph (<a href="#CD010260-fig-0001">Figure 1</a>; <a href="#CD010260-fig-0002">Figure 2</a>). Results of meta‐analyses were interpreted depending on the findings with respect to risk of bias. </p> <div class="figure" id="CD010260-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010260-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010260-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010260-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD010260-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment:</p> <p> <ul id="CD010260-list-0025"> <li> <p>for time‐to‐event data, we used HRs with 95% CI, where possible;</p> </li> <li> <p>for dichotomous outcomes, we used RRs with 95% CI.</p> </li> </ul> </p> </section> <section id="CD010260-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>There were no unit of analysis issues.</p> </section> <section id="CD010260-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data for any of the outcomes.</p> </section> <section id="CD010260-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials that could not be ascribed to sampling variation (<a href="./references#CD010260-bbs2-0043" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), and by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD010260-bbs2-0032" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London (UK): BMJ Publication Group, 2001.">Deeks 2001</a>). If there was evidence of substantial heterogeneity, the possible reasons for the heterogeneity were investigated and reported. </p> </section> <section id="CD010260-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not examine funnel plots corresponding to meta‐analysis of the primary outcome to assess the potential for small‐study effects such as publication bias, as stated in the protocol a priori, due to the fact that meta‐analyses of only three trials were possible. </p> </section> <section id="CD010260-sec-0037"> <h4 class="title">Data synthesis</h4> <p>If sufficient clinically similar trials were available, we pooled their results in meta‐analyses. </p> <p> <ul id="CD010260-list-0026"> <li> <p>For time to event data, we pooled HRs using the generic inverse variance facility of Review Manager 5 (<a href="./references#CD010260-bbs2-0074" title="Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </li> <li> <p>We used random‐effects models with inverse variance weighting for all meta‐analyses (<a href="./references#CD010260-bbs2-0034" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>). </p> </li> </ul> </p> </section> <section id="CD010260-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had intended to conducted subgroup analysis in the meta‐analysis of progression and DFS, grouping trials by whether the trial measured progression or DFS. However, this was not possible due to the lack of statistical heterogeneity and sparse data, but it may be considered in update of the review (see <a href="#CD010260-sec-0117">Differences between protocol and review</a>). </p> </section> <section id="CD010260-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a meta‐analysis of three trials assessing NACT and hysterectomy versus radiotherapy alone. </p> <p>We performed a meta‐analysis of two trials assessing NACT and hysterectomy versus chemoradiotherapy alone. </p> </section> <section id="CD010260-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account issues related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and external validity (such as directness of results) (<a href="./references#CD010260-bbs2-0054" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchünemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;23(2):81.">Langendam 2013</a>; <a href="./references#CD010260-bbs2-0078" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Schünemann 2020</a>)<i>.</i> We created summary of findings tables based on the methods described the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010260-bbs2-0045" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>) and using <a href="./references#CD010260-bbs2-0039" title="GRADEpro GDT. Version accessed 1 February 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> (<a href="./references#CD010260-bbs2-0039" title="GRADEpro GDT. Version accessed 1 February 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We used the GRADE checklist and GRADE Working Group certainty of evidence definitions (<a href="./references#CD010260-bbs2-0060" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82.">Meader 2014</a>). We downgraded the evidence from 'high' certainty by one level for serious (or by two for very serious) concerns for each limitation and grade as follows. </p> <p> <ul id="CD010260-list-0027"> <li> <p><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p><b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We presented summary of findings tables reporting the following outcomes listed in order of priority: </p> <p> <ul id="CD010260-list-0028"> <li> <p>OS.</p> </li> <li> <p>PFS or DFS.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Severe adverse events and toxicity.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010260-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010260-sec-0041"></div> <section id="CD010260-sec-0042"> <h3 class="title">Description of studies</h3> <p>We searched for RCTs assessing the role of hysterectomy in combination with chemotherapy or radiotherapy, or both, versus chemoradiotherapy alone. </p> <section id="CD010260-sec-0043"> <h4 class="title">Results of the search</h4> <p>The search strategy identified 968 unique references. We read the abstracts and excluded those that did not meet the inclusion criteria at this stage. We retrieved 20 articles in full and after full‐text screening excluded six references for the reasons described in the <a href="./references#CD010260-sec-0129" title="">Characteristics of excluded studies</a> table. Eleven studies met our inclusion criteria and are described in the <a href="./references#CD010260-sec-0128" title="">Characteristics of included studies</a> table (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>; <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>). See PRISMA flow chart for further details of study selection process (<a href="#CD010260-fig-0003">Figure 3</a>). Three studies are ongoing (<a href="./references#CD010260-bbs2-0018" title="TuH , HuangH , QuyangY , LiuQ , XianB , SongK , et al. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study. International Journal of Gynecological Cancer2021;31:129-33. ">CSEM 006 study</a>; <a href="./references#CD010260-bbs2-0019" title="Reis FihloPT , AndradeJM , BatistaMP , SousaCB , OliveiraTH , ArrudaGV , et al. Neoadjuvant chemotherapy and radical surgery versus chemoradiation for stage IB2, IIA2, IIB cervical cancer: a randomized controlled trial. Annals of Oncology2018;29(Suppl 8):VIII357-8. ">Reis Fihlo 2018</a>; <a href="./references#CD010260-bbs2-0020" title="ShanmugamS , GovindasamyG , HussainS , ManiJ . Comparison of neoadjuvant chemotherapy followed by radical hysterectomy and neoadjuvant chemoradiation followed by radical hysterectomy with concurrent chemoradiation in locally advanced carcinoma cervix (FIGO Stage IB2, IIA2, IIB): interim results of a randomized control study. Journal of South Asian Federation of Obstetrics and Gynecology2019;11(1):35-43. ">Shanmugam 2019</a>). </p> <div class="figure" id="CD010260-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010260-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Searches of the grey literature did not identify any additional studies.</p> </section> <section id="CD010260-sec-0044"> <h4 class="title">Included studies</h4> <p>The 11 included studies randomised 2683 women, all of whom were assessed for primary survival outcomes at the end of the studies (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>; <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>). </p> <p>The review identified the following treatment comparisons for the 11 included studies.</p> <p> <ul id="CD010260-list-0029"> <li> <p>Hysterectomy (radical) with NACT versus chemoradiotherapy alone (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>). </p> </li> <li> <p>Hysterectomy (simple or radical) with NACT versus radiotherapy alone (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). </p> </li> <li> <p>Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone (<a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>). </p> </li> <li> <p>Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone (<a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>). </p> </li> <li> <p>Hysterectomy (radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy (<a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>). </p> </li> </ul> </p> <p>The duration of follow‐up of participants varied from 36 to 98 months. In <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, the women who were last seen alive had a median follow‐up of 9.6 years (range 0.3 to 16.1 years). In <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>, the median follow‐up was 8.2 years (95% CI 7.8 to 8.6). </p> <p>The certainty of the evidence in this review was low or very low for all comparisons of outcomes other than for NACT and radical hysterectomy versus radiotherapy alone. The certainty of the evidence for OS and progression or DFS was moderate and was mainly downgraded due to concerns regarding risk of bias in individual trials. The trials in all the comparisons were at high or moderate risk of bias. </p> <section id="CD010260-sec-0045"> <h5 class="title">Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone</h5> <p>One multicentre RCT included 620 participants with FIGO Stage IB<sub>2</sub>, IIA (greater than 4 cm) or IIB cervical cancer (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>). Both patient groups received cisplatin‐based chemotherapy. In the NACT plus surgery group, women received neoadjuvant cisplatin‐based chemotherapy on day one. Treatment was repeated every 21 days. Within six weeks after the last chemotherapy course, and with a cumulative minimum of 225 mg/m<sup>2</sup>, women underwent a type III to V Piver‐Rutledge radical hysterectomy. Women with positive lymph nodes or tumour invasion into the parametria or less than 5 mm from the resection borders after surgery received standard adjuvant external‐beam radiotherapy once daily, five days a week, for 5.0 to 5.6 weeks (25 to 28 treatment days) followed by external boost radiotherapy or brachytherapy for one or two days In the concurrent radiotherapy group, radiation consisted of 45 Gy to 50 Gy plus boost concurrent with weekly cisplatin chemotherapy (40 mg/m<sup>2</sup> per week). Adjuvant hysterectomy was allowed, but not recommended, in cases of histologically confirmed residual tumour. Participants in both groups were evaluated for OS at five years (primary endpoint) and OS, PFS, toxicity and quality of life (secondary endpoints). </p> <p><a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a> was a single‐centre RCT that included women with cervical cancer Stage 1B<sub>2</sub>, IIA or IIB disease. The NACT plus surgery group received three cycles of paclitaxel (175 mg/m<sup>2</sup>) and carboplatin (dosed to an area under curve of 5 to 6) once every three weeks. Participants underwent clinical response assessment after the second and third cycles of chemotherapy. Participants who had no response or disease progression at these time points crossed over to receive definitive CCRT, whereas responders underwent surgery three to four weeks after the third cycle of chemotherapy. </p> <p>Participants assigned to the NACT plus surgery group underwent Piver‐Rutledge class III radical abdominal hysterectomy, bilateral pelvic lymphadenectomy and lower para‐aortic lymph node sampling by expert gynaecological oncologists. Surgery was abandoned in participants with intraoperative findings of either unresectable primary tumour or lymph node disease, and these participants were treated with definitive concurrent chemoradiation. Participants assigned to the concurrent chemoradiation group and those who were crossed over from the NACT plus surgery group received standard external‐beam radiation to the whole pelvis and brachytherapy. They received an external radiation dose of 40 Gy in 20 fractions with 2 Gy per fraction and a midline shield at 20 Gy, followed by intracavitary radiation to 'point A' as follows: either two applications of a low‐dose rate of 30 Gy each or five applications of a high‐dose rate of 7 Gy each. Radiation doses were modified to respect tumour, rectal and bladder constraints. These women also received five cycles of cisplatin (40 mg/m<sup>2</sup>), administered once every week starting with external‐beam radiotherapy. Participants in the NACT plus surgery group who underwent radical hysterectomy were given adjuvant therapy (radiotherapy or CCRT) as per protocol‐defined criteria, in accordance with published evidence. On the basis of histopathological evaluation of the surgical specimen, adjuvant chemoradiation was given in the presence of any one of the following features: lymph node metastasis, positive surgical margins or parametrial involvement. Adjuvant radiotherapy alone was given based on the presence of any two of the following features: deep cervical stromal invasion, lymphovascular invasion or tumour size greater than 4 cm. Participants in both groups were evaluated at protocol‐defined time points to evaluate response, monitor for relapse and assess toxicity. </p> <p>In <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>, both patient groups received platinum‐based chemotherapy. Participants assigned to the chemoradiotherapy group received external beam radiotherapy (EBRT; 45 Gy to 50 Gy) followed by brachytherapy. Participants assigned to the NACT plus surgery group, had radical hysterectomy and pelvic lymphadenectomy. Participants in both groups were evaluated for short‐term complications within 30 days of completion of treatment and long‐term complications that were reported within two years after treatment. </p> </section> <section id="CD010260-sec-0046"> <h5 class="title">Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone </h5> <p>Three RCTs randomised 571 women compared NACT and hysterectomy (simple or radical) versus radiotherapy alone (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> included women with Stage IB<sub>2</sub> to III cervical cancer, <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> included women with IB to IIA bulky disease and <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a> had only women with Stage IIIB disease. The median age in each arm was similar in <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> and <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> (range 46 to 52 years), whereas in <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>, women were significantly older in the radiotherapy arm (mean age 53 in the NACT and hysterectomy arm versus 60 years in the radiotherapy arm). All women in <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> and <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a> and most in <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> had squamous cell cancers. In <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> and <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>, the Eastern Cooperative Oncology Group performance status was zero for most eligible women. <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a> did not report performance status. </p> <p>In <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>, the NACT regimen was not predetermined; minimal requirements were a cisplatin‐containing regimen with a 240 mg/m<sup>2</sup> or greater total cisplatin dose with a maximum of two additional drugs, administered over six to eight weeks. After NACT, the women were clinically reassessed and classified as suitable or unsuitable for radical surgery. Participants who were unsuitable for radical surgery were treated with radiotherapy. Surgery consisted of radical hysterectomy (type III to V) plus systematic (at least 20 nodes to be resected) pelvic lymphadenectomy (aortic lymphadenectomy was optional). Postoperative radiotherapy was given in participants with positive surgical resection margins or metastatic nodes, or both. In the case of node metastasis, the choice of adjuvant treatment was based on the institution's policy (e.g. chemotherapy, external‐beam radiotherapy or no further therapy). Adjuvant treatment was given to 48 (29%) participants in the surgical group; 38 (23%) participants in the surgical group underwent adjuvant radiotherapy. </p> <p>Conventional radiotherapy consisted of external‐beam, megavoltage radiotherapy (45 Gy to 50 Gy) to the whole pelvis over five to six weeks. In the presence of metastatic pelvic nodes an extra dose of 5 Gy to 7 Gy was administered. Low‐dose rate brachytherapy (20 Gy to 30 Gy to the tumour volume) was provided two to four weeks after external radiotherapy. Aortic node metastases, when present, were irradiated (45 Gy per five weeks, followed by a 5 Gy boost if residual disease was eventually detected) with extended fields encompassing pelvic and aortic volume or at the end of pelvic irradiation, in the case of a pelvic complete remission. Salvage treatments were allowed in women who showed progressive disease. </p> <p>In <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>, the NACT was cisplatin and vincristine, followed by bleomycin. Two to four weeks after the completion of NACT, participants underwent a type III radical abdominal hysterectomy and pelvic lymphadenectomy. The adnexae were usually left in women aged 40 years or less if the gross appearance of the adnexae was normal. </p> <p>The radiotherapy usually included a combination of external radiotherapy and high‐dose rate brachytherapy; with 40 Gy to 44 Gy whole pelvic irradiation. The para‐aortic lymph nodes were not routinely included in the treatment field. Parametria received up to 50 Gy. If bulky tumour persisted after 44 Gy of irradiation, external‐beam doses to the lower pelvis were increased to 50 Gy to 54 Gy without central block followed by brachytherapy, or to 70 Gy without brachytherapy. The median cumulative dose to 'point A' in this treatment protocol was 70 Gy. Thirty‐seven participants were treated using this method. The postoperative radiotherapy was given by using techniques similar to those described above. The dose to the whole pelvis was 44 Gy to 45 Gy, and that to the true pelvis was 50 Gy to 54 Gy. After external radiotherapy, brachytherapy was given in two to three fractions with a total dose of 4 Gy/0.5 cm to 6 Gy/0.5 cm below the vaginal mucosa. </p> <p>Participants in the NACT arm had a higher incidence of receiving adjuvant therapy with either radiotherapy or chemotherapy after the scheduled treatment than those in the radiotherapy arm, who received radical hysterectomy as the adjuvant therapy. Of the 68 women in the NACT arm, 62 underwent hysterectomy and 19 of those had adjuvant radiotherapy, six had adjuvant chemotherapy and two had chemoradiotherapy. </p> <p>In <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>, the NACT regimen consisted of cisplatin, bleomycin and mitomycin for three courses every four weeks. If the tumour was surgically removable, a radical hysterectomy was performed with bilateral salpingo‐oophorectomy and pelvic lymphadenectomy, and then radiotherapy was given at 40 Gy to the whole pelvic region. If the tumour progressed or relapsed, combined chemotherapy of bleomycin, vincristine, mitomycin and cisplatin (BOPM) was given, and then irinotecan with cisplatin as the third line. If the local tumour was inoperable, radiotherapy was given at 40 Gy to the whole pelvic region with 20 Gy brachytherapy, followed by BOPM chemotherapy. </p> <p>The radiotherapy group received radiotherapy to the whole pelvic region in 20 fractions totalling 40 Gy. The total dose delivered to 'point B' as a boost dose with midline shield coverage was 20 Gy. The total dose delivered by brachytherapy was 24 Gy to 30 Gy. The pelvic field extended from the upper margin of L5 to the mid‐portion of the obturator foramen or the lowest level of disease, with a 3 cm margin, and laterally 1.5 cm to 2 cm beyond the lateral margins of the bony pelvic wall. The duration of the radiotherapy was four weeks. In cases with local recurrence or progression of the primary lesion, chemotherapy was added, which included BOMP, irinotecan with cisplatin, and cisplatin or carboplatin alone. When distant metastasis occurred, the researchers added radiotherapy, or the single lesion was surgically removed. </p> <p>All three studies assessed OS (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>), one study also assessed PFS (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>) and two studies also assessed DFS (<a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). However, the definition of DFS in <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> was absence of persistent or recurrent disease, so this appeared to be a combination of progression and DFS. It was possible to include all three studies in a meta‐analyses of OS and PFS or DFS as HR estimates were either explicitly reported, deduced (<a href="./references#CD010260-bbs2-0069" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>), or obtained via personal correspondence (<a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> reported severe toxicity and complications and <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> reported tumour response to treatment and toxicity. <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a> did not report adverse events. None of the three studies reported quality of life outcomes. </p> </section> <section id="CD010260-sec-0047"> <h5 class="title">Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</h5> <p>Two studies, which included 374 women, compared preoperative radiotherapy and radical hysterectomy versus radiotherapy alone (<a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>). <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> included 256 eligible women with Stage IB<sub>2</sub> disease (tumour size 4 cm to 8 cm); <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> included 118 women with Stage IIA disease as well as Stage IB (but women with a tumour more than 5 cm were excluded). The age distribution was comparable in the two groups in both trials, but additional information was not reported in <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>. In <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, just over 75% of the women were 50 years old or under. Most women in both trials had squamous cell carcinoma of the cervix. Additional baseline information was not reported in the <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> trial; but the performance status of women in <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> was generally good (more than 76% in both arms with performance status of 0 and more than 20% with performance status of 1). <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> did not mention whether the participants were evaluated clinically or radiologically after radiotherapy in order to assess the tumour response and residual disease. </p> <p>In <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, the daily fraction size was 180 Gy and external treatment carried to a total dose of 40 Gy for the radiation alone and 45 Gy for the adjuvant hysterectomy regimens. Both groups received brachytherapy one to two weeks after completing external treatment. The brachytherapy dose prescription was different between the treatment arms; the radiation alone group received 40 Gy with a total dose of 80 Gy to 'point A', while those who had hysterectomy received only 30 Gy with a total dose of 75 Gy to 'point A'. A minimum dose of 55 Gy was prescribed to 'point B' for both regimens. All irradiation was completed within 10 weeks. The surgical group then underwent simple hysterectomy with removal of tubes and ovaries, if present, two to six weeks after completion of all irradiation. </p> <p>In <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>, participants who were treated with preoperative radiotherapy and surgery received 20 Gy whole pelvis irradiation and one brachytherapy for 5000 to 6000 milligram‐hours (approximately 5 Gy to 6 Gy low‐dose rate given over six days), followed two to six weeks later by a radical hysterectomy and bilateral pelvic lymphadenectomy (up to the bifurcation of the common iliac vessels). The dose to the cervix was about 70 Gy and to the pelvic lymph nodes 30 Gy. </p> <p>Treatment with irradiation alone in <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> consisted of 10 Gy to 20 Gy delivered to the whole pelvis and an additional parametrial dose to total of 50 Gy to the external iliac lymph nodes combined with two brachytherapy insertions for a total of approximately 7500 milligram‐hours (65 Gy to 70 Gy to 'point A'). The dose to the paracervical tissues was about 85 Gy and to the pelvic lymph nodes 60 Gy. </p> <p><a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> assessed OS, pelvic‐free survival and the rate of pelvic recurrence. <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> assessed the five‐year tumour‐free actuarial survival, the sites of failure after therapy and treatment complications. </p> </section> <section id="CD010260-sec-0048"> <h5 class="title">Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</h5> <p><a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a> included 61 women with FIGO Stage IB<sub>2</sub> or II cervical cancer with a complete clinical and radiological response after chemoradiotherapy, randomly allocated to the treatment arms: hysterectomy or no hysterectomy. The median age and stage distribution was similar in both groups (45 years in the chemoradiotherapy and hysterectomy arm and 44 years in the chemoradiotherapy and no hysterectomy arm). Half of the women had FIGO Stage IB<sub>2</sub> and half Stage II disease. More than 80% of participants in each group had squamous cell cancer. The performance status of the included women was not described. </p> <p>Radiotherapy was delivered to the pelvis for a total dose of 45 Gy to 50 Gy, in five fractions of 1.8 Gy to 2 Gy per week, followed one to two weeks later by brachytherapy. Most women in both groups had one application of brachytherapy at 15 Gy. CCRT was cisplatin during external radiotherapy. A complete clinical and radiological response (based on magnetic resonance imaging (MRI)) was evaluated six to eight weeks after brachytherapy. </p> <p>Hysterectomy could be performed via laparotomy or a laparoscopy and could be extrafascial or radical (type II according to the Piver classification) according to the preoperative examination. A selective or complete pelvic lymphadenectomy was optional and could be performed if lymphadenopathy was detected during surgery. </p> <p>The trial gave HRs for OS and recurrence‐free survival as well as reporting the site of first recurrence. Morbidity was not reported after confirmation from the study authors. The median duration of follow‐up was 3.8 years (range 0.4 to 5.8 years) when the trial was closed early because of poor accrual. </p> <p><a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a> included 102 participants with LACC and compared chemoradiotherapy and radical hysterectomy and pelvic lymph node dissection versus chemoradiotherapy alone. Fifty‐two participants were included in the hysterectomy arm and 50 in the chemoradiotherapy alone arm. </p> <p>Women who met the inclusion criteria were first treated with CCRT.</p> <p>The radiotherapy plan was as follows: the linear accelerator was used for external pelvic irradiation, and the intracavitary <sup>192</sup>Ir was used for radiotherapy. Stage 1: the whole basin irradiation before and after the field or left and right field irradiation, four or five times a week, each time 2.25 Gy or 1.8 Gy, pelvic centre total dose 30 Gy. Stage 2: the lead block protected the uterus, and the uterus continued to be irradiated from the front and back, five times a week, 1.8 Gy to 2.0 Gy each time, and the total periuterine dose was 15 Gy to 20 Gy. At the beginning of the second stage of external irradiation, intracavitary and the back of the cavity were performed at the same time once a week, with 4.6 Gy to 7.0 Gy at 'point A' and total of 35 Gy to 42 Gy at 'point A'. Chemotherapy regimen: cisplatin alone: 35 mg/m<sup>2</sup> to 40 mg/m<sup>2</sup>, once a week. Surgical treatment: participants in the experimental group underwent radical surgery four to six weeks after the completion of CCRT. For radical total hysterectomy and pelvic lymphadenectomy, 3 cm of paracervical and vaginal tissues were removed. </p> <p>The outcomes of the study included recurrence and OS rate using. As outcome indicators they used: short‐term efficacy evaluation: evaluate the efficacy according to the tumour regression before and after treatment; complete remission: complete regression of the tumour by gynaecological examination and imaging examination; partial remission: tumour volume reduction of 50% or less; stability of disease: tumour volume reduction of 50% or less; progression of disease: tumour enlargement or presence of new lesions. Complete remission plus partial remission indicated effective treatment. </p> </section> <section id="CD010260-sec-0049"> <h5 class="title">Hysterectomy (radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy </h5> <p><a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a> included 211 women aged 18 to 70 years with a histological diagnosis of untreated FIGO Stage IB<sub>2</sub> to IIB cervical cancer and no evidence of para‐aortic lymph node involvement. It was reported that these 211 women were randomly allocated to either brachytherapy after external‐beam radiotherapy with chemotherapy or radical hysterectomy after external‐beam radiotherapy with chemotherapy. Women were ineligible for the study if they had previously received chemotherapy or radiotherapy. The median age, and stage distribution, was similar in both groups (44 years in the brachytherapy arm and 45 years in the hysterectomy arm). The median performance status (Karnofsky's) score was 90 and the median tumour size was 32 mm in both arms. Most participants in each treatment arm had FIGO Stage IIB disease (70% of participants in the brachytherapy arm and 74% in the hysterectomy arm). More than 80% of participants in each group had squamous cell cancer. </p> <p>Participants received 50.4 Gy external‐beam radiotherapy to the entire pelvic region in 28 sessions of 1.8 Gy/day, five days/week, over the six weeks of chemotherapy. Immediately after completion of external‐beam radiotherapy with chemotherapy, participants in the brachytherapy underwent low‐dose rate brachytherapy of 30 Gy to 35 Gy delivered to 'point A', to result in a cumulative dose of 80 Gy to 85 Gy combining external‐beam radiotherapy and brachytherapy. The cumulative external‐beam radiotherapy and brachytherapy dose to 'point B' (the pelvic wall) was 55 Gy to 65 Gy. </p> <p>Within four to six weeks after the external‐beam radiotherapy with chemotherapy, participants in the hysterectomy group were submitted to type III radical hysterectomy and bilateral pelvic lymph node dissection and para‐aortic lymph node sampling, if the multidisciplinary team judged the disease could be resected obtaining margins free of disease. Postoperative low‐dose rate brachytherapy was mandated in participants in the hysterectomy are only if the surgical specimen revealed positive surgical margins and was administered within four weeks after surgery at a median dose of 30 Gy to the vaginal mucosa delivered to a depth of 0.5 cm. </p> <p>The trial gave HRs for OS and PFS. The trial also reported pathological response; operative complications; toxicity to chemoradiation with cisplatin and gemcitabine; long‐term complications; and late complications including proctitis, cystitis and hydronephrosis. Only late complications were reported in a breakdown by treatment arm. The median duration of follow‐up was 36 months (range 3 to 80 months). </p> </section> </section> <section id="CD010260-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded six full‐text studies.</p> <p> <ul id="CD010260-list-0030"> <li> <p>Five studies included women who received hysterectomy or surgical staging in both arms (<a href="./references#CD010260-bbs2-0012" title="KatsumataN , YoshikawaH , KobayashiH , SaitoT , KuzuyaK , NakanishiT , et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). British Journal of Cancer2013;108(10):1957-63. ">Katsumata 2013</a>; <a href="./references#CD010260-bbs2-0013" title="KeysHM , BundyBN , StehmanFB , MuderspachLI , ChafeWE , SuggsCL , et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New England Journal of Medicine1999;340(15):1154-61. ">Keys 1999</a>; <a href="./references#CD010260-bbs2-0014" title="SardiJE , GiaroliA , SananesC , FerreiraM , SoderiniA , BermudezA , et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecologic Oncology1997;67(1):61-9. ">Sardi 1997</a>; <a href="./references#CD010260-bbs2-0015" title="SunH , XinJ , LuZ , WangN , LiuN , GuoQ . Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer. Cellular Physiology and Biochemistry2013;32(5):1528-40. ">Sun 2013</a>; <a href="./references#CD010260-bbs2-0017" title="YangZ , ChenD , ZhangJ , YaoD , KunG , WangH , et al. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: a randomized multicenter study. Gynecologic Oncology2016;141(2):231-9. ">Yang 2016</a>). </p> </li> <li> <p>One study compared surgery versus radiotherapy in women with early‐stage carcinoma of the cervix (<a href="./references#CD010260-bbs2-0016" title="SundforK , TropeCG , KjorstadKE . Radical radiotherapy versus brachytherapy plus surgery in carcinoma of the cervix 2A and 2B. Long-term results from a randomized study 1968-1980. Acta Oncologica1996;35(Suppl 8):99-107. ">Sundfor 1996</a>). </p> </li> </ul> </p> </section> <section id="CD010260-sec-0051"> <h4 class="title">Studies awaiting classification</h4> <p>We found no studies awaiting classification.</p> </section> <section id="CD010260-sec-0052"> <h4 class="title">Ongoing studies</h4> <section id="CD010260-sec-0053"> <h5 class="title">Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone</h5> <p><a href="./references#CD010260-bbs2-0019" title="Reis FihloPT , AndradeJM , BatistaMP , SousaCB , OliveiraTH , ArrudaGV , et al. Neoadjuvant chemotherapy and radical surgery versus chemoradiation for stage IB2, IIA2, IIB cervical cancer: a randomized controlled trial. Annals of Oncology2018;29(Suppl 8):VIII357-8. ">Reis Fihlo 2018</a> is an ongoing study and the final results will be available in 2023 (personal communication with the authors). Both participant groups (Stage IB<sub>2</sub>, IIA, or IIB) will receive platinum‐based chemotherapy. Participants assigned to the NACT and radical hysterectomy group will receive chemotherapy every 21 days for six weeks. Within six weeks after the last chemotherapy course, women will undergo a type III to V Piver‐Rutledge radical hysterectomy. Women with positive lymph nodes or tumour invasion into the parametria or less than 5 mm from the resection borders after surgery will receive standard adjuvant external‐beam radiotherapy once daily, five days a week, for 5.0 to 5.6 weeks (25 to 28 treatment days) followed by external boost radiotherapy or brachytherapy for one or two days. Participants assigned to the CCRT group will receive standard therapy comprising cisplatin‐based chemotherapy once weekly for six weeks. Adjuvant hysterectomy will be allowed, but not recommended, in cases of histologically confirmed residual tumour. Participants in both groups will be evaluated for OS, PFS, toxicity of the regimens and quality of life. </p> <p><a href="./references#CD010260-bbs2-0018" title="TuH , HuangH , QuyangY , LiuQ , XianB , SongK , et al. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study. International Journal of Gynecological Cancer2021;31:129-33. ">CSEM 006 study</a> is an ongoing study assessing DFS of women with Stage IIB cervical cancer randomised to NACT combined with surgery versus CCRT. </p> </section> <section id="CD010260-sec-0054"> <h5 class="title">Hysterectomy (radical) with chemoradiotherapy versus hysterectomy with neoadjuvant chemotherapy versus chemoradiotherapy alone </h5> <p><a href="./references#CD010260-bbs2-0020" title="ShanmugamS , GovindasamyG , HussainS , ManiJ . Comparison of neoadjuvant chemotherapy followed by radical hysterectomy and neoadjuvant chemoradiation followed by radical hysterectomy with concurrent chemoradiation in locally advanced carcinoma cervix (FIGO Stage IB2, IIA2, IIB): interim results of a randomized control study. Journal of South Asian Federation of Obstetrics and Gynecology2019;11(1):35-43. ">Shanmugam 2019</a> is an ongoing RCT where all three participant groups with LACC will receive cisplatin and paclitaxel chemotherapy. Women assigned to the CCRT group will receive cisplatin (75 mg/m<sup>2</sup>) and paclitaxel (175 mg/m<sup>2</sup>) given within a three‐week interval between the two cycles along with concurrent radiotherapy of EBRT 50 Gy (2 Gy for 25 doses) followed by brachytherapy of 21 Gy (7 Gy for 3 doses) completed within eight weeks. Women assigned to the preoperative chemoradiation plus radical hysterectomy group will receive cisplatin (75 mg/m<sup>2</sup>) and paclitaxel (175 mg/m<sup>2</sup>) given within a three‐week interval between the two cycles along with concurrent radiotherapy of 50 Gy EBRT (2 Gy for 25 doses) followed by radical hysterectomy within three weeks after completion of radiotherapy. Women assigned to the preoperative chemotherapy plus radical hysterectomy group will receive cisplatin (75 mg/m<sup>2</sup>) and paclitaxel (175 mg/m<sup>2</sup>) given within a three‐week interval for three cycles followed by radical hysterectomy within three weeks after completion of chemotherapy. The outcomes of the study will be OS, PFS, overall response rate, complete clinical response, partial clinical response and quality of life. </p> <p>For further details of the excluded studies see the <a href="./references#CD010260-sec-0129" title="">Characteristics of excluded studies</a> table. </p> </section> </section> </section> <section id="CD010260-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>Nine studies were at overall high risk of bias (<a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>; <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>), and <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> (which satisfied four of the criteria that we used to assess risk of bias) and <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> (which satisfied three items) were at moderate to high risk of bias (see <a href="#CD010260-fig-0001">Figure 1</a>). </p> <section id="CD010260-sec-0056"> <h4 class="title">Allocation</h4> <p>Only <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>, <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, and <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> reported the method of generation of the sequence of random numbers used to allocate women to the treatment arms, but they did not report concealment of this allocation sequence from participants and the healthcare professionals involved in the trials. The other eight trials did not report on the method of sequence generation, although two trials reported adequate concealment of allocation (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>). Allocation concealment was unclear in nine trials (<a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>; <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>). </p> </section> <section id="CD010260-sec-0057"> <h4 class="title">Blinding</h4> <p>Since it was not possible to blind participants and clinicians to these particular interventions, performance bias may have been an issue in all 11 included trials. Only one trial reported adequate blinding (low‐risk of detection bias; <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>), so the other 10 trials may have been prone to detection bias. </p> </section> <section id="CD010260-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>At least 80% of eligible women who were randomised were assessed at the endpoint in nine trials (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>), but this was unclear in two trials (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>). Two trials did not use intention‐to‐treat analyses (<a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>). </p> </section> <section id="CD010260-sec-0059"> <h4 class="title">Selective reporting</h4> <p>Five studies reported pertinent outcomes, although none reported quality of life outcomes (low risk of reporting bias; <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>). Two studies did not report adverse events or toxicity (high risk of reporting bias; <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). One study did not report OS despite the fact that the number of women who had died would have been known since disease progression was defined as the number of women whose disease had progressed or died (high risk of reporting bias; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>). This raised concern about a significant reporting bias. <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>, <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>, and <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a> were either in abstract form only or inadequately reported primary survival outcomes, so it was difficult to judge whether outcomes were selectively reported (unclear risk of reporting bias). </p> </section> <section id="CD010260-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>It was unclear whether any additional forms of bias may have been present in all studies so this item was scored at unclear risk of bias, although over 25% of participants in each arm deviated from the protocol in <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> and so this study was at high risk of bias for this item. </p> </section> </section> <section id="CD010260-sec-0061"> <h3 class="title" id="CD010260-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD010260-tbl-0001"><b>Summary of findings 1</b> Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone for women with locally advanced cervical cancer</a>; <a href="./full#CD010260-tbl-0002"><b>Summary of findings 2</b> Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone for women with locally advanced cervical cancer</a>; <a href="./full#CD010260-tbl-0003"><b>Summary of findings 3</b> Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</a>; <a href="./full#CD010260-tbl-0004"><b>Summary of findings 4</b> Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</a>; <a href="./full#CD010260-tbl-0005"><b>Summary of findings 5</b> Hysterectomy (simple or radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy</a> </p> <section id="CD010260-sec-0062"> <h4 class="title">Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone</h4> <p>Three trials included 1364 women and compared NACT and hysterectomy versus chemoradiotherapy alone (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>). See <a href="./full#CD010260-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD010260-sec-0063"> <h5 class="title">Overall survival</h5> <p>Two studies, assessing 1253 participants, reported OS (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>). There was no evidence of a difference in risk of death between women who received NACT plus hysterectomy and those who received chemoradiotherapy alone (HR 0.94, 95% CI 0.76 to 1.16; moderate‐certainty evidence; <a href="./references#CD010260-fig-0004" title="">Analysis 1.1</a>). The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) was not important (I<sup>2</sup> = 0%). </p> <p><a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a> included 620 participants with Stage IB<sub>2</sub> to IIB cervical cancer and compared NACT plus surgery (314 participants) with standard chemoradiotherapy (312 participants). Five‐year OS was 72% in the NACT plus surgery arm and 76% in the standard chemoradiotherapy arm (difference 4.0%, 95% CI –4% to 12%; HR 0.87, 95% CI 0.65 to 1.17; P = 0.332). The trial reported 191 (31%) deaths with a median follow‐up of 8.2 years (interquartile range (IQR) 7.8 to 8.6). Five‐year OS was 72% in the NACT plus surgery arm and 76% in the standard chemoradiotherapy arm (difference 4.0%, 95% CI –4% to 12%). Additional radiotherapy was given to 113 (36.3%) participants in the NACT plus surgery arm. Additional surgery was performed in nine (2.9%) participants in the standard chemoradiotherapy arm. </p> <p><a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a> included 633 women aged 18 to 65 years with histologically confirmed squamous cell carcinoma of the cervix with 1994 FIGO Stage IB<sub>2</sub>, IIA or IIB disease. It compared NACT plus surgery with chemoradiotherapy. Five‐year OS rates in the NACT plus surgery group was 75.4% compared with 74.7% in the concurrent chemoradiation group (HR 1.03, 95% CI 0.75 to 1.40; P = 0.87). </p> </section> <section id="CD010260-sec-0064"> <h5 class="title">Disease‐free survival</h5> <p>In <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>, five‐year DFS in the NACT plus surgery group was 69.3% compared with 76.7% in the concurrent chemoradiation group (HR 1.38, 95% CI 1.02 to 1.87; P = 0.038). In subgroup analyses, there was evidence of a difference in DFS detriment in the NACT plus surgery group in participants with FIGO Stage IIB disease, with a significant test of interaction between treatment effect and Stages IIA and IIB disease. In women with Stage IIB disease, the five‐year DFS rates in the NACT plus surgery group was 67.2% and concurrent chemoradiation group was 79.3% (unadjusted HR for DFS in the NACT plus surgery group 1.90, 95% CI 1.25 to 2.89; P = 0.003). </p> <p>In <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>, the five‐year DFS in the NACT plus surgery group was 56.9% compared with 65.6% in the CCRT group (P = 0.021), mostly for Stage IIB disease. However, the authors noted that the first imaging measurement occurred systematically earlier in the neoadjuvant plus surgery arm than in the chemoradiotherapy arm. </p> </section> <section id="CD010260-sec-0065"> <h5 class="title">Quality of life</h5> <p>None of the studies reported quality of life.</p> </section> <section id="CD010260-sec-0066"> <h5 class="title">Severe adverse events</h5> <p><a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a> reported no toxic deaths. Short‐term severe adverse events (G3 or higher) occurred more frequently with NACT plus surgery (35%) than with chemoradiotherapy (21%; P &lt; 0.001). In total, there were 198 serious adverse events (SAEs): 145 in the NACT plus surgery arm versus 53 in the standard chemoradiotherapy arm. Within the group of SAEs, there were 109 serious adverse reactions (SARs) with NACT plus surgery, and 35 SARs with chemoradiotherapy. Nearly all were chemotherapy related. In the NACT plus surgery arm, 238 (76%) women underwent surgery. </p> <p>Main reasons for not having surgery as per protocol were toxicity (25/74, 34%), progressive disease (18/74, 24%) and insufficient response to NACT (12/74, 16%). </p> <section id="CD010260-sec-0067"> <h6 class="title">Toxicity</h6> <p>In <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>, in the NACT plus surgery group compared with the concurrent chemoradiation group, there was a lower rate of rectal (5.7% with NACT plus surgery versus 13.3% with chemoradiotherapy; P = 0.002), bladder (2.8% with NACT plus surgery versus 7.3% with chemoradiotherapy; P = 0.017), and vaginal (19.9% with NACT plus surgery versus 36.9% with chemoradiotherapy; P = 0.001) toxicity occurring or persisting 90 days after treatment completion. However, 24 months after treatment completion, there was no difference in rectal and bladder toxicities between groups, whereas vaginal toxicity continued to occur at a lower rate in the NACT plus surgery group (12.0% with NACT plus surgery versus 25.6% with chemoradiotherapy; P = 0.001). </p> </section> <section id="CD010260-sec-0068"> <h6 class="title">Treatment‐related morbidity</h6> <p><a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a> included 111 women with Stage IB<sub>2</sub> to III cervical cancer comparing the toxicity‐related morbidity of CCRT with NACT plus surgery. Participants were evaluated for short‐term complications within 30 days of completion of treatment and long‐term complications that were reported within two years after treatment. There were no treatment‐related deaths. Overall 89% of participants in the chemoradiotherapy arm and 73% in the NACT plus surgery arm had complications, with 18% in the NACT plus surgery arm experiencing recurrence and requiring adjuvant radiotherapy. </p> <p>In <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a> there were grade 3/4 complications related to surgery: 8 (3.3%) participants had bleeding, 10 (4.2%) operative lesions to ureter or bladder, 3 (1.2%) fistula, 7 (2.9%) others (sepsis, urinary tract infection and wound dehiscence). </p> </section> </section> </section> <section id="CD010260-sec-0069"> <h4 class="title">Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone </h4> <p>Three studies compared hysterectomy (simple or radical) with NACT versus radiotherapy alone (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). See <a href="./full#CD010260-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD010260-sec-0070"> <h5 class="title">Overall survival</h5> <p>Meta‐analysis of three studies, assessing 571 participants, found that women who received NACT plus hysterectomy had a lower risk of death compared with women who received radiotherapy alone (HR 0.71, 95% CI 0.55 to 0.93; moderate‐certainty evidence; <a href="./references#CD010260-fig-0005" title="">Analysis 2.1</a>) (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<sup>2</sup> = 0%). </p> </section> <section id="CD010260-sec-0071"> <h5 class="title">Progression‐free survival and disease‐free survival</h5> <p>Meta‐analysis of three studies, assessing 571 participants, found no difference in the risk of disease progression between women who received NACT plus hysterectomy and those who received radiotherapy alone (HR 0.75, 95% CI 0.53 to 1.05; moderate‐certainty evidence; <a href="./references#CD010260-fig-0006" title="">Analysis 2.2</a>) (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance might not have been important (I<sup>2</sup> = 20%). </p> </section> <section id="CD010260-sec-0072"> <h5 class="title">Severe adverse events</h5> <section id="CD010260-sec-0073"> <h6 class="title">Acute toxicity</h6> <p><a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> reported short‐term complications but it was not possible to make comparisons because participants were compared in terms of those who received NACT, hysterectomy and radiotherapy separately, and participants may have experienced more than one toxicity in each category (low‐certainty evidence). </p> <p><a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> reported 9/68 (13%) cases of grade 3 acute toxicity in the NACT plus hysterectomy group and 7/50 (22%) cases of severe acute toxicity (5/7 were grade 3) in the radiotherapy alone group. There was no evidence of a difference between groups (RR 1.32, 95% CI 0.47 to 3.71; low‐certainty evidence). Acute toxicities included nausea, vomiting, diarrhoea, liver and dermatological adverse effects. </p> </section> <section id="CD010260-sec-0074"> <h6 class="title">Long‐term complications and toxicity</h6> <p>In <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>, long‐term severe complications occurred in 32 (19.5%) women in the NACT arm and late severe morbidity with radiotherapy was observed in 39 (22%) women. There was no evidence of a difference in long‐term severe complications between NACT plus hysterectomy and radiotherapy alone (RR 0.86, 95% CI 0.49 to 1.50; low‐certainty evidence). </p> <p><a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> reported 9/68 (13%) cases of severe late toxicity (8/9 were grade 3) in the NACT plus hysterectomy group and 11/50 (22%) grade 3 cases in the radiotherapy alone group. There was no evidence of a difference between groups (RR 0.60, 95% CI 0.27 to 1.34; low‐certainty evidence). Late toxicities included intestinal obstruction, radiation cystitis, radiation proctitis and lower leg oedema. </p> </section> </section> </section> <section id="CD010260-sec-0075"> <h4 class="title">Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</h4> <p><a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> and <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> included 374 women and compared preoperative radiotherapy and radical hysterectomy versus radiotherapy alone. The trialists gave a breakdown by FIGO Stage and intervention group in <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> but did not report OS or use appropriate survival techniques to allow the trial to be pooled. See <a href="./full#CD010260-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD010260-sec-0076"> <h5 class="title">Overall survival</h5> <p>In <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, there was no evidence of a difference in the risk of death between women who received radiotherapy plus extrafascial hysterectomy and those who received radiotherapy alone (HR 0.89, 95% CI 0.61 to 1.29; low‐certainty evidence). </p> </section> <section id="CD010260-sec-0077"> <h5 class="title">Progression‐free survival</h5> <p>In <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, there was evidence of a difference in the risk of disease progression or death between women who received radiotherapy plus hysterectomy and those who received radiotherapy alone (HR 0.77, 95% CI 0.54 to 1.10; low‐certainty evidence). </p> </section> <section id="CD010260-sec-0078"> <h5 class="title">Tumour‐free actuarial survival at five years</h5> <p>In <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>, five‐year, tumour‐free actuarial survival for women with Stage IB was 80% with preoperative radiotherapy and surgery and 89% with radiotherapy alone. It was not reported how many women were Stage IB<sub>1</sub> and how many Stage IB<sub>2</sub> (the Stage IB<sub>2</sub> group was of interest for this Cochrane Review). Women with barrel‐shaped cervix (endocervical lesion with cervix diameter larger than 5 cm) were excluded. In Stage IIA, the five‐year tumour‐free survival was 79% in the preoperative radiotherapy and surgery group and 56% in the radiotherapy alone group. These differences were not significant (very low‐certainty evidence). </p> </section> <section id="CD010260-sec-0079"> <h5 class="title">Quality of life</h5> <p>None of the studies reported quality of life.</p> </section> <section id="CD010260-sec-0080"> <h5 class="title">Severe/serious adverse events</h5> <p>In the women with Stage IB disease in <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>, only 1/48 (2%) women experienced a severe complication (grade 3) in the radiotherapy and surgery group (ureteral stricture) whereas 5/40 experienced severe complications in the radiotherapy alone group (including rectovaginal fistula, vesicovaginal fistula, ureteral stricture and pelvic infection). This difference was not significant. Similarly in women with Stage IIA disease, 5/14 (40%) women experienced a severe complication in the radiotherapy and surgery group (including proctitis, rectal stricture, small bowel stricture and ureteral stricture) whereas only 1/16 experienced a severe complication in the radiotherapy alone group (rectal stricture). This difference was not significant (low‐certainty evidence). </p> <p><a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> stated that both treatment programmes were well tolerated and there did not appear to be a difference between groups in terms of adverse effects. There were 18/129 women with a grade 3 or 4 adverse effect in the hysterectomy and radiotherapy group and 19 cases in 18/121 women of severe adverse effects in the radiotherapy alone group. Two women in each group received no radiotherapy and were not included (low‐certainty evidence). </p> </section> </section> <section id="CD010260-sec-0081"> <h4 class="title">Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</h4> <p>Two studies compared hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone (<a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>) </p> <p><a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a> included 61 women and compared chemoradiotherapy and simple or radical hysterectomy versus chemoradiotherapy alone. <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a> included 102 women with LACC and compared chemoradiotherapy and radical hysterectomy with pelvic lymph node dissection versus chemoradiotherapy alone. Fifty‐two participants were included in the hysterectomy arm and 50 in the chemoradiotherapy alone arm. See <a href="./full#CD010260-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD010260-sec-0082"> <h5 class="title">Overall survival</h5> <p>OS was inadequately reported in <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a> and it was not possible to calculate an HR. OS time of the chemoradiotherapy plus surgery group was 6 to 40 months, median survival time was 23 months and three‐year survival rate was 82.7%. Total survival time of the chemoradiotherapy group was 5 to 41 months, the median survival time was 22.5 months and the three‐year survival rate was 81.8%. The trial authors reported no evidence of a difference between arms (Chi<sup>2</sup> = 0.338, P = 0.56; very low‐certainty evidence). </p> <p>The postoperative pathological data in the hysterectomy arm showed that the residual rate of non‐cancer was 82.7%, and the residual rate of cancer was 5.8%. </p> </section> <section id="CD010260-sec-0083"> <h5 class="title">Progression‐free survival</h5> <p>PFS was inadequately reported in <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a> and it was not possible to calculate an HR. PFS time of the chemoradiotherapy plus surgery group was 3 to 40 months, median survival time was 23 months and three‐year survival rate was 73.1%. PFS time of the chemoradiotherapy alone group was 5 to 41 months, median survival time was 22 months and three‐year survival rate was 64.8%. There was no evidence of a difference between groups (Chi<sup>2</sup> = 0.092, P = 0.76; very low‐certainty evidence). </p> <p><a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a> reported no evidence of a difference in three‐year event‐free (death) survival rate (86% in the chemoradiotherapy plus hysterectomy group and 97% in the chemoradiotherapy alone group; log rank P = 0.15; very low‐certainty evidence). </p> </section> <section id="CD010260-sec-0084"> <h5 class="title">Recurrence‐free survival at three years</h5> <p><a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a> reported no evidence of a difference in three‐year event‐free (recurrence) survival rate (72% in the chemoradiotherapy plus hysterectomy group and 89% in the chemoradiotherapy alone group; log rank P = 0.17; low‐certainty evidence). We did not attempt to calculate an HR using the methods of <a href="./references#CD010260-bbs2-0069" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a> due to this being a single trial analysis (very low‐certainty evidence). </p> <p>The authors reported that morbidity was studied in a further publication, but when we contacted them, they could not provide data on morbidity. </p> </section> <section id="CD010260-sec-0085"> <h5 class="title">Quality of life</h5> <p>The trial did not report quality of life.</p> </section> <section id="CD010260-sec-0086"> <h5 class="title">Severe adverse events</h5> <p>The trial did not adequately report SAEs.</p> </section> </section> <section id="CD010260-sec-0087"> <h4 class="title">Hysterectomy (radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy </h4> <p>One trial included 211 women and compared brachytherapy versus radical hysterectomy in women who had already received external‐beam chemoradiotherapy with gemcitabine plus cisplatin (<a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>). See <a href="./full#CD010260-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD010260-sec-0088"> <h5 class="title">Overall survival</h5> <p>There was no evidence of a difference in the risk of death between women in the brachytherapy group and those in the radical hysterectomy group (HR 0.65, 95% CI 0.35 to 1.21; P = 0.19; low‐certainty evidence). </p> </section> <section id="CD010260-sec-0089"> <h5 class="title">Progression‐free survival</h5> <p>There was no evidence of a difference in the risk of disease progression or death between women in the brachytherapy group and those in the radical hysterectomy group (HR 0.70, 95% CI 0.31 to 1.34; P = 0.24; low‐certainty evidence). </p> </section> <section id="CD010260-sec-0090"> <h5 class="title">Quality of life</h5> <p>The study did not report quality of life.</p> </section> <section id="CD010260-sec-0091"> <h5 class="title">Severe adverse events</h5> <section id="CD010260-sec-0092"> <h6 class="title">Severe late complications</h6> <p>There was no evidence of a difference in the proportion of women with severe late complications between groups (P = 0.53; low‐certainty evidence). There were four cases of grade 3 or 4 proctitis in the brachytherapy group and two cases in the radical hysterectomy group. There were three cases of severe cystitis in the brachytherapy group and none in the radical hysterectomy group, and there were no reported cases of grade 3 or 4 hydronephrosis in either group (low‐certainty evidence). </p> <p>Of the 211 participants in the trial, chemoradiotherapy with cisplatin and gemcitabine appeared to be reasonably well tolerated, although nearly a third of women experienced severe neutropenia (most grade 3). Of the 86 women who received a radical hysterectomy, the number of intraoperative and early surgical complications appeared to be reasonably low, with bleeding (9/86) being the most common (low‐certainty evidence). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010260-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010260-sec-0093"></div> <section id="CD010260-sec-0094"> <h3 class="title" id="CD010260-sec-0094">Summary of main results</h3> <p>We found 11 studies including 2683 women that met our inclusion criteria. These studies assessed the role of hysterectomy (radical or simple) in combination with chemotherapy or radiotherapy, or both, in the treatment of LACC. </p> <p>The RCTs were of varying methodological quality; most were at high risk of bias. These trials compared the following treatments for women with LACC (Stage IB<sub>2</sub> to III). </p> <p> <ul id="CD010260-list-0031"> <li> <p>Hysterectomy (radical) with NACT versus chemoradiotherapy alone (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>). </p> </li> <li> <p>Hysterectomy (simple or radical) with NACT versus radiotherapy alone (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). </p> </li> <li> <p>Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone (<a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>). </p> </li> <li> <p>Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone (<a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>). </p> </li> <li> <p>Hysterectomy (radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy (<a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>). </p> </li> </ul> </p> <p>Three trials included 1364 women and compared NACT and hysterectomy versus chemoradiotherapy alone (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>). </p> <p><a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a> compared NACT plus surgery with standard CCRT. The preliminary results of this study revealed no difference in five‐year OS between NACT plus hysterectomy and CCRT, indicating that quality of life and long‐term toxicity are important to decide optimal treatment. Overall toxicity was acceptable, occurred more frequently in the NACT plus surgery arm and was mainly related to NACT. The five‐year DFS in the NACT plus surgery group was worse compared with the concurrent chemoradiation group (P = 0.021), mostly for Stage IIB disease. However. the authors noted that the first imaging measurement occurred systematically earlier in the neoadjuvant plus surgery arm than in the chemoradiation arm and this may have affected this result. These first data also indicate that in the surgery arm short‐term toxicity due to NACT has influenced further treatment. Of note, additional treatment was given to a significantly greater number of participants in the NACT and surgery group versus the number of participants in the concurrent chemoradiation group. </p> <p><a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>, similarly to the EORTC trial, compared NACT plus surgery with standard CCRT. The five‐year DFS in the NACT plus surgery group was worse compared with the concurrent chemoradiation group, whereas there was no evidence of a difference in the corresponding five‐year OS rates. In subgroup analyses, the DFS detriment in the NACT plus surgery group was significant in women with FIGO Stage IIB disease, with a significant test of interaction between treatment effect and Stages IIA and IIB disease. </p> <p>Meta‐analysis of three studies, assessing 571 women, found that women who received NACT plus hysterectomy had less risk of death than those who received radiotherapy alone, but there was no difference in the proportion of women with disease progression or recurrence between groups (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). </p> <p><a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> reported no difference in long‐term severe complications between NACT plus hysterectomy and radiotherapy alone. Moreover, it has to be considered that 38 (23%) women who were operated on also underwent adjuvant radiotherapy and that 30% of these women were likely to present with severe late complications. </p> <p><a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a> found no difference in grade 3 acute toxicity and severe late toxicity between the NACT plus hysterectomy group and the radiotherapy alone group. </p> <p>In summary these data demonstrate a possible beneficial effect of NACT plus hysterectomy versus radiotherapy in terms of survival, but no difference in DFS. This difference may be due to the NACT, the adjuvant treatment,]or both, rather than hysterectomy since these also differed between groups. </p> <p><a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> and <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a> included 374 women and compared preoperative radiotherapy and hysterectomy versus radiotherapy alone. These two trials reported no differences in the risk of death or disease progression, five‐year tumour‐free actuarial survival and severe complications between women who received radiotherapy plus hysterectomy and those who received radiotherapy alone. </p> <p>Only <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a> described the OS and PFS in the subgroup of women with residual disease in the hysterectomy specimen. Women with grossly positive hysterectomy specimens progressed and died at almost seven times the rate compared to those with negative specimens. </p> <p><a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a> included 61 women and reported no difference in overall and recurrence‐free survival at three years between chemoradiotherapy and hysterectomy (simple or radical) versus chemoradiotherapy alone. The study did not report adverse events and morbidity data. </p> <p>Similarly, <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a> compared brachytherapy versus radical hysterectomy in 211 women who had already received chemoradiotherapy with gemcitabine plus cisplatin. They found no difference in the risk of death, disease progression or severe late complications between women in the brachytherapy group and those in the hysterectomy group. </p> <p>Harms of treatment, especially in terms of quality‐of‐life data, were poorly reported. Studies comparing the more modern standard treatment of chemoradiotherapy did not demonstrate a benefit with the addition of hysterectomy. </p> </section> <section id="CD010260-sec-0095"> <h3 class="title" id="CD010260-sec-0095">Overall completeness and applicability of evidence</h3> <p>All 11 included studies are relevant in terms of the patient population, types of interventions, effectiveness and outcomes. However, in six studies, the role of hysterectomy as adjuvant treatment is more difficult to assess because the women received different types of primary or neoadjuvant treatment compared with the group who had a hysterectomy (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). Three trials that compared NACT and hysterectomy versus radiotherapy alone appeared to have external validity and represented a wide geographic area including Italy, China and Japan (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a> was a multicentre trial. The generalisability of other studies was less strong as the comparisons differed across studies and only results of single studies could be reported, although some were from multiple centres, which strengthens their representativeness. </p> <p><a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a> included women who had a complete response after chemoradiotherapy. The remaining studies did not provide an assessment of the response before surgery. It is important to note that women with a complete response to treatment before surgery potentially have a better prognosis compared to women with residual disease, therefore, the role of adjuvant hysterectomy should be assessed in subgroups with similar prognostic factors (<a href="./references#CD010260-bbs2-0037" title="GadducciA , SartoriE , MagginoT , ZolaP , CosioS , ZizioliV , et al. Pathological response on surgical samples is an independent prognostic variable for patients with Stage IB2–IIB cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: an Italian multicenter retrospective study (CTF Study). Gynecologic Oncology2013;131(3):640-4. [DOI: 10.1016/j.ygyno.2013.09.029]">Gadducci 2013</a>; <a href="./references#CD010260-bbs2-0042" title="HequetD , MarchandE , PlaceV , FourchotteV , De La RochefordièreA , DridiS , et al. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study. European Journal of Surgical Oncology2013;39(12):1428-34. [DOI: 10.1016/j.ejso.2013.10.006]">Hequet 2013</a>; <a href="./references#CD010260-bbs2-0053" title="LandoniF , SartoriE , MagginoT , ZolaP , ZanagnoloV , CosioS , et al. Is there a role for postoperative treatment in patients with stage IB2-IIB cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecologic Oncology2014;132(3):611-7. [DOI: 10.1016/j.ygyno.2013.12.010]">Landoni 2014</a>). <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a> is a multicentre, RCT comparing neoadjuvant hysterectomy plus surgery compared to chemoradiotherapy alone; however, at the moment we only have preliminary results. </p> <p>Overall, studies reported survival data well, although data on harms were poorly reported. These data are insufficient to recommend, outside of clinical trials, adding hysterectomy to chemoradiotherapy/radiotherapy in women with LACC. </p> <p>Currently, the standard treatment for LACC is platinum‐based CCRT (<a href="./references#CD010260-bbs2-0028" title="Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD008285. [DOI: 10.1002/14651858.CD008285]">CCCMAC 2010</a>; <a href="./references#CD010260-bbs2-0063" title="National Cancer Institute. NCI clinical announcement. United States Department of Health and Human Services, Public Health Service, National Institutes of Health February 1999; Bethesda (MD).">NCI 1999</a>). Although in this review we included older RCTs that did not use chemotherapy, the more relevant studies in modern clinical practice are those that use platinum‐based treatment. </p> <p>The evidence appears to be of low or very low‐certainty for all comparison outcomes other than for NACT and radical hysterectomy versus radiotherapy alone (<a href="./references#CD010260-bbs2-0040" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">GRADE Working Group 2004</a>). The certainty of the evidence for overall and progression or DFS was moderate and was mainly downgraded due to concerns regarding risk of bias in individual trials. The trials in all of the comparisons were at high or moderate risk of bias. More trials that assess identical medical management with and without hysterectomy may test the robustness of the findings of this review as further research is likely to have an important impact on our confidence in the estimates of effect. The meta‐analyses in the review found that women who received NACT plus hysterectomy had less risk of death (so prolonged survival) than those who received radiotherapy alone (HR 0.71, 95% CI 0.55 to 0.93; see <a href="./references#CD010260-fig-0005" title="">Analysis 2.1</a>), but there was no difference in disease progression. However, it is difficult to assess the impact of the hysterectomy given that it was in combination with NACT, since much of this difference may have been due to the chemotherapy component controlling microscopic distant disease rather than improving local control. Using the GRADE approach (<a href="./references#CD010260-bbs2-0040" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">GRADE Working Group 2004</a>), the evidence summarised by this review is not sufficient to drive changes in clinical practice. Uncertainty about the additive effects of hysterectomy on a number of different outcomes justifies its evaluation in addition to chemoradiotherapy in future clinical trials. </p> </section> <section id="CD010260-sec-0096"> <h3 class="title" id="CD010260-sec-0096">Quality of the evidence</h3> <p>We reviewed 11 heterogeneous studies, assessing 2683 women, that evaluated the role of hysterectomy with radiotherapy or chemotherapy, or both, in women with LACC. Losses to follow‐up were small but the trials generally scored poorly for other risk of bias items and were potentially at high risk of bias. The number of women in the trials varied considerably with the largest including 633 women (<a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>), and the smallest including only 42 women (<a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>). </p> <p>We included trials with LACC but these trials had a different number of cases for each stage of disease (Stage IB<sub>2</sub> to IIIB), therefore, the results may have differed across trials. </p> <p>The type and dose of medical treatment (chemotherapy, radiotherapy or both) were heterogeneous across the trials. </p> <p>The baseline indicators to measure the general health of participants in the studies were incompletely reported. Six studies mentioned the performance status of women (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>), and not all studies reported important clinical details such as the size of the tumour and information on residual disease. </p> <p>Primary survival outcomes were largely well reported in the trials included in the first publication of this review (<a href="./references#CD010260-bbs2-0086" title="KokkaF , BryantA , BrockbankE , PowellM , OramD . Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD010260. [DOI: 10.1002/14651858.CD010260.pub2]">Kokka 2015</a>). HRs were reported explicitly, deduced or obtained via correspondence so time‐to‐event data were analysed using appropriate survival methods in meta‐analyses or, where possible, in single study reports. However, updated trials included in this update of the review were inadequately reported to include survival outcomes in meta‐analyses. </p> <p>There was incomplete reporting of harms and not all studies reported quality of life. Eight studies reported morbidity by treatment arm (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0007" title="KhanN . Chemoradiation versus neoadjuvant chemotherapy and surgery in locally advanced squamous cell cervical cancer: a randomized study in a north east Nigerian center. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne, Australia2014. ">Khan 2014</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>), but three trials did not (<a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>; <a href="./references#CD010260-bbs2-0011" title="ZhengJ , HuangB , ZhouY , HuangS , ChenS , LietL . Concomitant chemoradiation followed by radical surgery for locally advanced cervical cancer patients preliminary result from RCT. Chinese Journal of Evidence-Based Medicine2017;17(1):1-6. ">Zheng 2017</a>). It is important to describe the adverse effects of adjuvant hysterectomy in women with LACC receiving multiple treatments as the available literature suggests severe morbidity (<a href="./references#CD010260-bbs2-0042" title="HequetD , MarchandE , PlaceV , FourchotteV , De La RochefordièreA , DridiS , et al. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study. European Journal of Surgical Oncology2013;39(12):1428-34. [DOI: 10.1016/j.ejso.2013.10.006]">Hequet 2013</a>; <a href="./references#CD010260-bbs2-0057" title="MabuchiS , KozasaK , KimuraT . Radical hysterectomy after radiotherapy for recurrent or persistent cervical cancer. International Journal of Gynaecology and Obstetrics2017;139(2):185-91.">Mabuchi 2017</a>). </p> <p>In <a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>, 28% of women deviated from the protocol in each arm (58/210 in the NACT and hysterectomy arm, 55/199 in the radiotherapy arm), which is high. An additional concern was that of the 210 women in the NACT and hysterectomy arm, 75 received radiotherapy, 37 due to not being suitable for hysterectomy and 38 after hysterectomy. Only 164/210 (78%) in the NACT and hysterectomy arm had surgery. This cross‐over and the protocol deviation are potentially highly significant sources of bias. </p> <p>Four studies did not mention the route of hysterectomy, that is open or laparoscopic (<a href="./references#CD010260-bbs2-0001" title="Benedetti-PaniciP , GreggiS , ColomboA , AmorosoM , SmaniottoD , GiannarelliD , et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology2002;20(1):179-88. ">Benedetti‐Panici 2002</a>; <a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>). <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a> indicated how many cases had laparoscopic or open procedures; however the study outcomes, including morbidity, were not subgrouped regarding this factor. Evidence suggests that laparoscopic procedures may have less morbidity than open procedures when performed for the appropriate group of women (<a href="./references#CD010260-bbs2-0026" title="BijenCB , VermeulenKM , MouritsMJ , deBockGH . Costs and effects of abdominal versus laparoscopic hysterectomy: systematic review of controlled trials. PLoS One2009;4(10):e7340.">Bijen 2009</a>; <a href="./references#CD010260-bbs2-0031" title="ColomboPE , BertrandMM , GutowskiM , MourregotA , FabbroM , Saint-AubertB , et al. Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results. Gynecologic Oncology2009;114(3):404-9.">Colombo 2009</a>; <a href="./references#CD010260-bbs2-0068" title="ParkJY , KimDY , KimJH , KimYM , KimYT , NamJH . Laparoscopic versus open radical hysterectomy in patients with stage IB2 and IIA2 cervical cancer. Journal of Surgical Oncology2013;108(1):63-9.">Park 2013</a>). Future studies should ideally consider this factor. </p> <p>In <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, surgical staging of lymph nodes was optional and was performed on 57 (22%) women equally divided between the two study arms. Any women with metastasis to the para‐aortic nodes was ineligible for the RCT. Of the 103 women who did not have prerandomisation surgical staging, 54 (52%) had a hysterectomy and lymph node sampling procedure. Of these, seven (13%) had positive para‐aortic nodes. Since the surgical staging of lymph nodes was optional and it was performed in a subgroup of women, it is likely that this study was biased as far as the homogeneity of the staging and the prognosis of included women. </p> <p>In <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>, there were three different dose ranges for brachytherapy during the study period. </p> <p>For the update of this review, we identified two RCTs with similar design characteristics (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>). The EORTC trial results have been given so far in abstracts and oral presentations; the full paper is yet to be published. We understand there is a plan for a meta‐analysis of these two studies. </p> <p>We identified three ongoing trials that may provide more evidence (<a href="./references#CD010260-bbs2-0018" title="TuH , HuangH , QuyangY , LiuQ , XianB , SongK , et al. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study. International Journal of Gynecological Cancer2021;31:129-33. ">CSEM 006 study</a>; <a href="./references#CD010260-bbs2-0019" title="Reis FihloPT , AndradeJM , BatistaMP , SousaCB , OliveiraTH , ArrudaGV , et al. Neoadjuvant chemotherapy and radical surgery versus chemoradiation for stage IB2, IIA2, IIB cervical cancer: a randomized controlled trial. Annals of Oncology2018;29(Suppl 8):VIII357-8. ">Reis Fihlo 2018</a>; <a href="./references#CD010260-bbs2-0020" title="ShanmugamS , GovindasamyG , HussainS , ManiJ . Comparison of neoadjuvant chemotherapy followed by radical hysterectomy and neoadjuvant chemoradiation followed by radical hysterectomy with concurrent chemoradiation in locally advanced carcinoma cervix (FIGO Stage IB2, IIA2, IIB): interim results of a randomized control study. Journal of South Asian Federation of Obstetrics and Gynecology2019;11(1):35-43. ">Shanmugam 2019</a>). </p> <p>The overall certainty of the evidence for NACT and radical hysterectomy versus radiotherapy alone was moderate for survival outcomes and low for adverse events. All other comparisons provided low‐certainty evidence, mainly because of poor reporting of outcomes and sparse data where results were based on single trials. The imprecision in single trials may be due to there being no significant difference between two treatments or an absence of evidence, which may come to light with greater statistical power. None of the studies reported quality of life and adverse events were incompletely reported, so the certainty of the evidence was low or very low for these outcomes in all comparisons. The trials in all comparisons were at high or moderate risk of bias. Further research is likely to have an important impact on our confidence in the estimates of effects and may change the estimates in the treatment comparisons based on single trial results and for outcomes that were incompletely reported; but we are quite confident of the reliability of the meta‐analysis of NACT and hysterectomy versus radiotherapy alone (571 participants) for the assessment of survival outcomes. </p> <p>The certainty of the evidence in all other comparisons was low or very low for all outcomes. </p> <p>This review identified that more evidence is needed and there is justification for evaluating the role of hysterectomy in combination with other adjuvant and neoadjuvant treatment options in clinical trials. </p> </section> <section id="CD010260-sec-0097"> <h3 class="title" id="CD010260-sec-0097">Potential biases in the review process</h3> <p>We performed a comprehensive search including electronic databases and the grey literature. Two review authors independently assessed references and extracted data. We restricted the included studies to RCTs, which provide the strongest level of evidence available. Hence, we have attempted to reduce bias in the review process. </p> <p>One significant threat to the validity of the review is the possibility of publication bias, that is, studies that had negative results did not find the treatments to have been effective may not have been published. We were unable to assess this possibility as the meta‐analyses included just three studies and the review 11 studies in total. </p> </section> <section id="CD010260-sec-0098"> <h3 class="title" id="CD010260-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>Treatment of LACC should be individualised and limited to the minimum number of treatment modalities to yield the best cure with minimal complications. The US National Cancer Institute alert in February 1999 stated that chemoradiotherapy should be considered for all women with cervical cancer. This was based on significant improvements in PFS and OS when cisplatin‐based chemotherapy was administered during radiotherapy for various stages of cervical cancer (<a href="./references#CD010260-bbs2-0061" title="MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New England Journal of Medicine1999;340(15):1137-43.">Morris 1999</a>; <a href="./references#CD010260-bbs2-0063" title="National Cancer Institute. NCI clinical announcement. United States Department of Health and Human Services, Public Health Service, National Institutes of Health February 1999; Bethesda (MD).">NCI 1999</a>; <a href="./references#CD010260-bbs2-0075" title="RosePG , BundyBN , WatkinsEB , ThigpenJT , DeppeG , MaimanMA , et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine1999;340(15):1144-53.">Rose 1999</a>; <a href="./references#CD010260-bbs2-0084" title="WhitneyCW , SauseW , BundyBN , MalfetanoJH , HanniganEV , Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology1999;17(5):1339-48.">Whitney 1999</a>). </p> <p>Chemoradiotherapy is considered by many groups (in North America, Europe) as the standard treatment for LACC (<a href="./references#CD010260-bbs2-0028" title="Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD008285. [DOI: 10.1002/14651858.CD008285]">CCCMAC 2010</a>; <a href="./references#CD010260-bbs2-0041" title="GreenJA , KirwanJM , TierneyJF , SymondsP , FrescoL , CollingwoodM , et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet2001;358(9284):781-6.">Green 2001</a>). This includes pelvic external‐beam radiotherapy with concurrent platinum‐based chemotherapy followed by brachytherapy to boost the central disease response. Alternatively, LACC has been treated with primary radiotherapy alone. </p> <p>In other countries, the lack of access to radiotherapy and the presumed poor control of metastatic disease has necessitated the use of NACT and hysterectomy. Chemotherapy is administered before other treatments to reduce the tumour volume and, therefore, to make women with clinically inoperable disease amenable to surgery (<a href="./references#CD010260-bbs2-0077" title="SardiJ , SananesC , GiaroliA , MayaG , di PaolaG . Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecologic Oncology1990;38(3):486-93.">Sardi 1990</a>; <a href="./references#CD010260-bbs2-0014" title="SardiJE , GiaroliA , SananesC , FerreiraM , SoderiniA , BermudezA , et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecologic Oncology1997;67(1):61-9. ">Sardi 1997</a>). </p> <p>With adjuvant hysterectomy the primary site of cervical cancer is removed. This approach may be preferred by women and the physicians as the 'initial site' of the tumour is removed. However, it is not certain if this approach results in improved survival. This systematic review of the currently available published trials found no evidence that adjuvant hysterectomy improves OS in women with LACC treated with radiotherapy or chemotherapy, or both. In women with a complete response to chemoradiotherapy or radiotherapy there is no obvious benefit. Women with a partial response to chemoradiotherapy or radiotherapy represent a poorer prognostic group; the role of adjuvant hysterectomy in this group of women is still debated (<a href="./references#CD010260-bbs2-0022" title="AzriaE , MoriceP , Haie-MederC , ThouryA , PautierP , LhommeC , et al. Results of hysterectomy in patients with bulky residual disease at the end of chemoradiotherapy for stage IB2/II cervical carcinoma. Annals of Surgical Oncology2005;12:332-7.">Azria 2005</a>; <a href="./references#CD010260-bbs2-0042" title="HequetD , MarchandE , PlaceV , FourchotteV , De La RochefordièreA , DridiS , et al. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study. European Journal of Surgical Oncology2013;39(12):1428-34. [DOI: 10.1016/j.ejso.2013.10.006]">Hequet 2013</a>; <a href="./references#CD010260-bbs2-0047" title="HouvenaeghelG , LelievreL , ButtarelliM , JacquemierJ , CarcopinoX , ViensP , et al. Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma. European Journal of Surgical Oncology2007;33:498-503.">Houvenaeghel 2007</a>; <a href="./references#CD010260-bbs2-0067" title="OtaT , TakeshimaN , TabataT , HasumiK , TakizawaK . Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. British Journal of Cancer2008;99(8):1216-20.">Ota 2008</a>; <a href="./references#CD010260-bbs2-0081" title="SunL , ShengX , JiangJ , LiX , LiuN , LiuY , et al. Surgical morbidity and oncologic results after concurrent chemoradiation therapy for advanced cervical cancer. International Journal of Gynaecology and Obstetrics2014;125(2):111-5. [DOI: 10.1016/j.ijgo.2013.07.041]">Sun 2014</a>). </p> <p>In <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>, women with grossly positive hysterectomy specimens progressed and died at almost seven‐times the rate of those with negative specimens. None of the rest of the included RCTs provided information or appeared to have analysed the subgroup of women with residual disease following concurrent chemotherapy; this subgroup of women is quite challenging to treat and involves debate at the multidisciplinary team meetings. Hysterectomy after radiotherapy/concurrent chemotherapy is not the standard of care in most high‐income countries. In cases of suboptimal chemoradiotherapy, due to poor radiotherapy resources, adjuvant hysterectomy may have a role (<a href="./references#CD010260-bbs2-0051" title="KundargiRS , GuruprasadB , HanumantappaN , RathodPS , DeviUK , BafnaUD . The role of surgery in locally advanced carcinoma of cervix after sub-optimal chemoradiation: Indian scenario. South Asian Journal of Cancer2013;2(3):137-9.">Kundargi 2013</a>), as it is impossible to deliver a curative dose of radiation via external beam alone. In other settings, hysterectomy for residual central (i.e. cervix or uterus) disease after completion of radiotherapy/concurrent chemotherapy (external beam and brachytherapy) the usual practice is to wait as a minimum of 12 weeks as it is possible that the disease will respond slowly and surgery after radiotherapy can be challenging. In situations where it has not been possible to place a brachytherapy applicator (the brachytherapy may have failed because there is still very bulky disease), then careful consideration of surgical excision is required (whether one will achieve complete clearance surgically before proceeding). In such cases, surgery may involve an exenteration; management in all such cases needs to be individualised as exenterative surgery may not be appropriate even if technically feasible. One of the concerns regarding surgery following chemoradiotherapy is surgery‐related morbidity. The <a href="./references#CD010260-bbs2-0028" title="Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD008285. [DOI: 10.1002/14651858.CD008285]">CCCMAC 2010</a> meta‐analysis showed that chemoradiotherapy alone can cause severe adverse effects; chemotherapy can cause significant acute toxicity and radiotherapy can cause late complications that are difficult to reverse. Surgery following these modalities can be challenging as the quality of the tissues and the potential for healing are adversely affected by the preceding treatments. <a href="./references#CD010260-bbs2-0042" title="HequetD , MarchandE , PlaceV , FourchotteV , De La RochefordièreA , DridiS , et al. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study. European Journal of Surgical Oncology2013;39(12):1428-34. [DOI: 10.1016/j.ejso.2013.10.006]">Hequet 2013</a> and <a href="./references#CD010260-bbs2-0036" title="FerrandinaG , ErcoliA , FagottiA , FanfaniF , GallottaV , MargaritiAP , et al. Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications. Annals of Surgical Oncology2014;21(5):1692-9.">Ferrandina 2014</a> found that the morbidity following surgery was high, suggesting an under‐reporting of morbidity data in the included studies. Well‐designed studies are required to assess the adverse effects of adjuvant hysterectomy following concurrent chemotherapy/radiotherapy of women with LACC, including studies where advanced radiotherapy techniques such as intensity‐modulated radiotherapy are used; intensity‐modulated radiotherapy has been associated with reduced toxicity (<a href="./references#CD010260-bbs2-0023" title="BaojuanY , LinZ , HaiyanC , QiL , YunyanZ , YashuangZ . Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis. Radiation Oncology2012;7:197.">Baojuan 2012</a>; <a href="./references#CD010260-bbs2-0056" title="LinAJ , KiddE , DehbashtuF , SiegelB , MuticS , ThakerPH , et al. Intensity modulated radiation therapy and image guided adapted brachytherapy for cervix cancer. International Journal of Radiation Oncology, Biology, Physics2019;103(5):1088-97.">Lin 2019</a>; <a href="./references#CD010260-bbs2-0058" title="MarjanovicD , KarapandzicVP , RundicSS , TomasevicA , SaricM , MiskovicI , et al. Implementation of intensity-modulated radiotherapy and comparison with three-dimensional conformal radiotherapy in the postoperative treatment of cervical cancer. Journal of B.U.ON.2019;24(5):2028-34.">Marjanovic 2019</a>), hence adjuvant hysterectomy may cause less morbidity. </p> <p>In five included studies there was no difference in the rate of local and distant recurrences between the two arms (<a href="./references#CD010260-bbs2-0002" title="CetinaL , González-EncisoA , CantúD , CoronelJ , Pérez-MontielD , HinojosaJ , et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2–IIB cervical cancer patients. Annals of Oncology2013;24:2043-7. [DOI: 10.1093/annonc/mdt142]">Cetina 2013</a>; <a href="./references#CD010260-bbs2-0006" title="KeysHM , BundyBN , StehmanFB , OkagakiT , GallupDG , BurnettAF , et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecologic Oncology2003;89(3):343-53. ">Keys 2003</a>; <a href="./references#CD010260-bbs2-0008" title="MoriceP , RouanetP , ReyA , RomestaingP , HouvenaeghelG , BoulangerJC , et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist2012;17(1):64-71. ">Morice 2012</a>; <a href="./references#CD010260-bbs2-0009" title="NoriyukiY , HiroshiS , KazukoF , KimihiroN , TsuyomuI . A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix. Journal Of Gynecologic Surgery2010;26(2):105-13. ">Noriyuki 2010</a>; <a href="./references#CD010260-bbs2-0010" title="PerezCA , CamelHM , KaoMS , HedermanMA . Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecologic Oncology1987;27(2):129-40. ">Perez 1987</a>). In <a href="./references#CD010260-bbs2-0003" title="Chang T-C, Lai C-H, Hong J-H, HsuehS , Huang K-G, Chou H-H, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology2000;18(8):1840-7. ">Chang 2000</a>, there was a reduction in the local recurrence rate (9% versus 21%) and a slight decrease in the distant recurrence rate (10% versus 13%) in women who received concurrent radiation and cisplatin and radical hysterectomy compared with those who received radiotherapy alone. The beneficial role of hysterectomy on this difference is unclear because, as mentioned earlier, evidence suggests that it is the addition of cisplatin that reduces the risk of local and distant recurrence (<a href="./references#CD010260-bbs2-0061" title="MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New England Journal of Medicine1999;340(15):1137-43.">Morris 1999</a>; <a href="./references#CD010260-bbs2-0063" title="National Cancer Institute. NCI clinical announcement. United States Department of Health and Human Services, Public Health Service, National Institutes of Health February 1999; Bethesda (MD).">NCI 1999</a>; <a href="./references#CD010260-bbs2-0071" title="Peters WA 3rd, LiuPY , Barrett RJ 2nd, StockRJ , MonkBJ , BerekJS , et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology2000;18(8):1606-13.">Peters 2000</a>; <a href="./references#CD010260-bbs2-0075" title="RosePG , BundyBN , WatkinsEB , ThigpenJT , DeppeG , MaimanMA , et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine1999;340(15):1144-53.">Rose 1999</a>; <a href="./references#CD010260-bbs2-0084" title="WhitneyCW , SauseW , BundyBN , MalfetanoJH , HanniganEV , Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology1999;17(5):1339-48.">Whitney 1999</a>). </p> <p>The most recent randomised studies have highlighted a possible worse result of NACT and surgery versus CCRT in the women with Stage IIB disease (<a href="./references#CD010260-bbs2-0004" title="KenterG , GreggiS , VergoteI , KatsarosD , KobierskiJ , MassugerL , et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IB2–IIB cervical cancer: EORTC55994. Journal of Gynecologic Cancer2019;37(15 suppl):5503-5503. ">EORTC 2019</a>; <a href="./references#CD010260-bbs2-0005" title="GuptaS , MaheswariA , ParabP , MahantshettyU , HawaldarR , SastriS , et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology2018;36:1548-55. ">Gupta 2018</a>). Meta‐analyses of these two studies and the results of the ongoing trial, <a href="./references#CD010260-bbs2-0018" title="TuH , HuangH , QuyangY , LiuQ , XianB , SongK , et al. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study. International Journal of Gynecological Cancer2021;31:129-33. ">CSEM 006 study</a>, should provide more evidence about the best practice in this subgroup of women. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010260-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/urn:x-wiley:14651858:media:CD010260:CD010260-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010260-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_t/tCD010260-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010260-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/urn:x-wiley:14651858:media:CD010260:CD010260-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010260-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_t/tCD010260-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010260-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/urn:x-wiley:14651858:media:CD010260:CD010260-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010260-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_t/tCD010260-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010260-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/urn:x-wiley:14651858:media:CD010260:CD010260-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hysterectomy (radical) with neoadjuvant chemotherapy (NACT) versus chemoradiotherapy alone, Outcome 1: Overall survival" data-id="CD010260-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_t/tCD010260-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Hysterectomy (radical) with neoadjuvant chemotherapy (NACT) versus chemoradiotherapy alone, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references#CD010260-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010260-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/urn:x-wiley:14651858:media:CD010260:CD010260-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hysterectomy (simple or radical) with neoadjuvant chemotherapy (NACT) versus radiotherapy alone, Outcome 1: Overall survival" data-id="CD010260-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_t/tCD010260-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Hysterectomy (simple or radical) with neoadjuvant chemotherapy (NACT) versus radiotherapy alone, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references#CD010260-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010260-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/urn:x-wiley:14651858:media:CD010260:CD010260-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hysterectomy (simple or radical) with neoadjuvant chemotherapy (NACT) versus radiotherapy alone, Outcome 2: Disease‐ or progression‐free survival" data-id="CD010260-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_t/tCD010260-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Hysterectomy (simple or radical) with neoadjuvant chemotherapy (NACT) versus radiotherapy alone, Outcome 2: Disease‐ or progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references#CD010260-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/media/CDSR/CD010260/image_n/nCD010260-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010260-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone for women with locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (radical) with neoadjuvant chemotherapy versus with chemoradiotherapy alone for women with locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> NACT + hysterectomy </p> <p><b>Comparison:</b> CCRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 58.5–98.4 months in the 2 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.94</b> (0.76 to 1.16) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1253</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 0% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DFS</b> </p> <p>Median follow‐up 58.5–98.4 months in the 2 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.38</b> (1.02 to 1.87) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>633</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5‐year DFS in the NACT + surgery group was 57% vs 65.6% in the chemoradiotherapy group (P = 0.021) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>620</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>SAEs and toxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>SAEs</i> </p> <p>In first trial, there were no toxic deaths reported.</p> <p>198 SAEs occurred: 145 in the NACT + surgery arm vs 53 in the CCRT arm.</p> <p>In the second trial there were 114 grade 3 or 4 SAEs: 92 in the NACT + surgery arm vs 22 in the CCRT arm </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198</p> <p>(1 RCT)</p> <p>114</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><i>Toxicity</i> </p> <p>In 1 trial, NACT + surgery group, compared with the chemoradiotherapy group, there was a lower rate of rectal (5.7% with NACT + surgery vs 13.3% with chemoradiotherapy; P = 0.002), bladder (2.8% with NACT + surgery vs 7.3% with chemoradiotherapy; P = 0.017), and vaginal (19.9% with NACT + surgery vs 36.9% with chemoradiotherapy; P = 0.001) toxicity occurring or persisting 90 days after treatment completion. However, 24 months after treatment completion, there was no difference in rectal and bladder toxicities between groups, whereas vaginal toxicity continued to occur at a lower rate in the NACT + surgery group (12.0% with NACT + surgery vs 25.6% with chemoradiotherapy; P = 0.001). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><i>Treatment‐related morbidity</i> </p> <p>No treatment‐related deaths in either chemoradiotherapy or NACT + surgery arm. Overall, 89% of participants in the chemoradiotherapy arm and 73% in the NACT + surgery arm had complications, with 18% in NACT + surgery arm experiencing recurrence and requiring adjuvant radiotherapy. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CCRT:</b> concurrent chemoradiotherapy; <b>DFS:</b> disease‐free survival; <b>HR:</b> hazard ratio; <b>NACT:</b> neoadjuvant chemotherapy; <b>SAE:</b> serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to concerns regarding the uncertainty of risk of bias in individual trials and only two trials in meta‐analysis (although it is arguable whether the number of included participants represented relatively sparse data).<br/><sup>b</sup>Downgraded two levels due to risk of bias and sparse data.<br/><sup>c</sup>Downgraded three levels due to incomplete and poor reporting of important adverse events and toxicities, sparseness of data and risk of bias concerns. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hysterectomy (radical) with neoadjuvant chemotherapy versus chemoradiotherapy alone for women with locally advanced cervical cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010260-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone for women with locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone for women with locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> neoadjuvant chemotherapy + radical hysterectomy </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 39–60 months in the 3 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.71</b> (0.55 to 0.93) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐ or progression‐free survival</b> </p> <p>Median follow‐up 39–60 months in the 3 trials</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.75</b> (0.53 to 1.05) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were varying definitions of disease‐ and progression‐free survival. However, we did not consider this merited further downgrading to low‐certainty evidence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Severe adverse events and toxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>Acute severe toxicity</i> </p> <p><b>RR 1.32</b> (0.47 to 3.71) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>Long‐term severe complications</i> </p> <p><b>RR 0.86</b> (0.49 to 1.50) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>409</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><i>Severe late toxicity</i> </p> <p><b>RR 0.60</b> (0.27 to 1.34) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to concerns regarding the uncertainty of risk of bias in individual trials.<br/><sup>b</sup>Downgraded two levels due to incomplete and poor reporting of important adverse events and toxicities and sparseness of data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hysterectomy (simple or radical) with neoadjuvant chemotherapy versus radiotherapy alone for women with locally advanced cervical cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010260-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> radiotherapy + hysterectomy (simple or radical) </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 9.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.89</b> (0.61 to 1.29) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 participants in each regimen (10% with radiotherapy + hysterectomy vs 9% with radiotherapy) were lost to follow‐up by 5 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> <p>Median follow‐up 9.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.77</b> </p> <p>(0.54 to 1.10)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 participants in each regimen (10% with radiotherapy + hysterectomy vs 9% with radiotherapy) were lost to follow‐up by 5 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tumour‐free actuarial survival at 5 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5‐year, tumour‐free actuarial survival for women with Stage IB was 80% in the preoperative radiotherapy + hysterectomy group and 89% in the radiotherapy group. In Stage IIA, these rates were 79% in the preoperative radiotherapy + hysterectomy group and 56% in the radiotherapy group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe/serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 trial stated that both treatment programmes were well tolerated and there were no differences between groups in adverse effects. There were 18/129 women with a grade 3 or 4 adverse effect in the radiotherapy + hysterectomy group and 19 cases in 18/121 women of severe adverse effects in the radiotherapy group. </p> <p>In another trial, only 1/48 (2%) women with Stage IB disease experienced a severe complication (grade 3) in the radiotherapy + hysterectomy group (ureteral stricture) whereas 5/40 experienced severe complications in the radiotherapy group (including rectovaginal fistula, vesicovaginal fistula, ureteral stricture and pelvic infection) (P &gt; 0.05). Similarly in women with Stage IIA disease, 5/14 (40%) women experienced a severe complication in the radiotherapy + hysterectomy group (including proctitis, rectal stricture, small bowel stricture and ureteral stricture) whereas only 1/16 women experienced a severe complication in the radiotherapy group (rectal stricture) (P &gt; 0.05). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>374</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative effect measures were not presented due to the crude combining of adverse events or sparse data, or both. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to sparse data leading to imprecision.<br/><sup>b</sup>Downgraded one level due to small number of trials and a lack of representation.<br/><sup>c</sup>Downgraded one level due to inadequate reporting of results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hysterectomy (simple or radical) with radiotherapy versus radiotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010260-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> chemoradiotherapy + hysterectomy (simple or radical) </p> <p><b>Comparison:</b> chemoradiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 3.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Overall survival was inadequately reported and it was not possible to calculate a hazard ratio. Overall survival time in the chemoradiotherapy + hysterectomy group was 6–40 months, median survival time was 23 months, and 3‐year survival rate was 82.7%. Total survival time in the chemoradiotherapy group was 5–41 months, median survival time was 22.5 months and 3‐year survival rate was 81.8%. Trial authors reported differences between arms were not statistically significant (P = 0.56). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression or event‐free survival</b> </p> <p>Median follow‐up 3.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival was inadequately reported in both trials and it was not possible to calculate a hazard ratio. In 1 trial, progression‐free survival time in the chemoradiotherapy + hysterectomy group was 3–40 months, median survival time was 23 months and 3‐year survival rate was 73.1%. The progression‐free survival time in the chemoradiotherapy alone group was 5–41 months, median survival time was 22 months and 3‐year survival rate was 64.8%. There was no significant difference between arms (P = 0.76). </p> <p>Another trial included 61 women and compared chemoradiotherapy + simple or radical hysterectomy vs chemoradiotherapy alone. There was no difference in 3‐year event‐free (death) survival rate (86% in the chemoradiotherapy + hysterectomy group vs 97% in the chemoradiotherapy alone group; log rank P = 0.15). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163<br/>(2 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not adequately reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe/serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not adequately reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to sparse data leading to imprecision.<br/><sup>b</sup>Downgraded one level due to small number of trials and a lack of representation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hysterectomy (simple or radical) with chemoradiotherapy versus chemoradiotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010260-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Hysterectomy (simple or radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hysterectomy (simple or radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with locally advanced cervical cancer </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> chemoradiotherapy + hysterectomy (simple or radical) </p> <p><b>Comparison:</b> chemoradiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> <p>Median follow‐up 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.65</b> (95% CI 0.35 to 1.21) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression or event‐free survival</b> </p> <p>Median follow‐up 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.70</b> (95% CI 0.31 to 1.34) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe late complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was no difference in the proportion of women with severe late complications in the brachytherapy and radical hysterectomy groups (P = 0.53). There were 4 cases of grade 3 or 4 proctitis in the brachytherapy group vs 2 cases in the radical hysterectomy group; 3 cases of severe cystitis in the brachytherapy group vs 0 in the radical hysterectomy group; 0 cases of grade 3 or 4 hydronephrosis in either group. </p> <p>Of the 211 participants, chemoradiotherapy with cisplatin and gemcitabine appeared to be reasonably well tolerated, although nearly a third of women experienced severe neutropenia (most grade 3). Of the 86 women who received a radical hysterectomy, the number of intraoperative and early surgical complications appeared to be reasonably low, with bleeding (9/86) being the most common. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to sparse data leading to imprecision.<br/><sup>b</sup>Downgraded one level due to small number of trials and a lack of representation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Hysterectomy (simple or radical) with chemoradiotherapy versus internal radiotherapy (brachytherapy) with chemoradiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010260-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of 2009 and 2018 FIGO staging of cervical cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Stage I (2018): carcinoma strictly confined to the cervix (extension to the uterine corpus should be disregarded) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2009 FIGO stage: description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2018 FIGO stage: description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IA: invasive carcinoma diagnosed only by microscopy, with maximum depth of invasion &lt;/= 5 mm and largest extension &lt;/= 7 mm</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IA: invasive carcinoma diagnosed only by microscopy, with maximum depth of invasion &lt; 5 mm</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>– Lateral extent of the carcinoma is no longer considered in distinguishing between FIGO Stage IA and IB carcinomas</b> </p> <p><b>– If margins of loop are involved patient is allocated to Stage IB1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0001"> <li> <p>IA1: measured stromal invasion &lt; 3 mm in depth and extension &lt;/= 7 mm</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0002"> <li> <p>IA1: measured stromal invasion &lt; 3 mm in depth</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0003"> <li> <p>IA2: measured stromal invasion &gt;/= 3 mm and &lt; 5 mm in depth and extension &lt;/= 7 mm</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010260-list-0004"> <li> <p>IA2: measured stromal invasion &gt;/= 3 mm and &lt; 5 mm in depth</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IB: clinically visible lesions limited to the cervix or preclinical cancers greater than Stage IA </i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>IB: invasive carcinoma with measured deepest invasion &gt;/= 5 mm (greater than Stage IA), lesion limited to the cervix uteri</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– See above</b> </p> <p><b>– LVSI must be commented upon, although does not affect FIGO stage</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD010260-list-0005"> <li> <p>IB1: clinically visible lesion &lt;/= 4 cm in greatest dimension</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB1: invasive carcinoma &gt;/= 5 mm depth of stromal invasion, and &lt; 2 cm in greatest dimension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– New stage category</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB2: invasive carcinoma &gt;/= 2 cm and &lt; 4 cm in greatest dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– New stage category</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB2: invasive carcinoma &gt; 4 cm in greatest dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IB3: invasive carcinoma &gt;/= 4 cm in greatest dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>– New stage category</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Adapted from <a href="./references#CD010260-bbs2-0080" title="SinghN , RousB , GanesanR . 2018 FIGO staging system for cervical cancer: summary and comparison with 2009 FIGO staging system. www.bgcs.org.uk/wp-content/uploads/2019/05/BAGP-2018-FIGO-Cervix-Ca-staging-doc-v1.2.pdf (accessed prior to 4 January 2021).">Singh 2019</a>.<br/>LVSI: lymphovascular space invasion. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of 2009 and 2018 FIGO staging of cervical cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/full#CD010260-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010260-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hysterectomy (radical) with neoadjuvant chemotherapy (NACT) versus chemoradiotherapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hysterectomy (radical) with neoadjuvant chemotherapy (NACT) versus chemoradiotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references#CD010260-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010260-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hysterectomy (simple or radical) with neoadjuvant chemotherapy (NACT) versus radiotherapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.55, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Disease‐ or progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.53, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hysterectomy (simple or radical) with neoadjuvant chemotherapy (NACT) versus radiotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010260.pub3/references#CD010260-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010260.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010260-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010260-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010260-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010260-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010260-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD010260-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD010260-note-0012">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD010260-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD010260-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010260-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010260-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010260\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010260\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010260\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010260\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010260\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010260.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010260.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010260.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010260.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010260.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727909797"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010260.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727909800"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010260.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb7949e1c937f',t:'MTc0MDcyNzkxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 